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1. Abstract
Peptide Nucleic Acid (PNA) has shown great potential in molecular diagnostics,
antisense/antigene therapy and nanotechnology. Like other synthetic nucleic acids and
artificial analogues, PNA has been extensively modified to achieve better performance in
these applications. To efficiently develop PNA probes for molecular diagnosis, this thesis
is focused on versatile functionalization of PNA via post-synthetic click chemistry.
Chapter 2 presents the synthesis of quencher-free PNA molecular beacons (MBs) targeting
a cystic fibrosis transmembrane conductance regulator (CFTR) sequence mutation. To
avoid the tedious synthesis of functionalized PNA monomers for probe development, a
simple approach to modify PNA oligomers by post-synthetic on-resin click chemistry was
developed. Precursor PNA MBs were prepared by incorporation of an Fmoc azide
monomer into the oligomer by automatic solid-phase peptide synthesis and subsequent
derivatization with pyrene moieties by copper-catalyzed azide-alkyne cycloaddition
(CuAAC) produced the functional MBs. Two pyrene-based quencher-free PNA molecular
beacons, a stemless MB and one possessing a stem-loop structure, both targeting a portion
of the cystic fibrosis gene, were successfully synthesized by this method. Fluorescence
studies showed that the stem-loop MB exhibited better discrimination of changes in
excimer/monomer ratios as compared to the stemless MB construct and showed promise
as MB for detection of this CFTR mutation.
Chapter 3 reports the synthesis of PNA MBs targeting CFTR mutation via a “click-coupleclick” method. Unlike the well-known synthetic procedure of conventional PNA MBs that
requires different protection strategies on the sites where fluorophores and quenchers are
attached, an on-resin “click-couple-click” approach that includes microwave-assisted onii

resin CuAAC of a quencher to PNA, coupling of an azide-containing PNA monomer and
another on-resin CuAAC of a fluorophore without the need of protection. By using this
method, various PNA MBs have been successfully synthesized and characterized.
Chapter 4 discloses the simultaneous, multiple conjugations of alkynyl-(Gd(III)-DOTA) to
a PNA oligomer possessing azide residues in a single post-synthetic CuAAC reaction. The
resulting probe, (Gd(III)-DOTA)4-PNA, has potential as a MRI contrast agent.
Conceptually by binding to the target, poly(rA) tail of mRNA, Gd ions would be
significantly loaded to a localized microenvironment, which may improve the
enhancement of contrast in MR images. The in vitro MR characteristics of this probe is
presented.
With the interest in the conjugation of gold nanoparticles (AuNPs) to PNA for the
development of targeted contrast agents for CT imaging, preliminary studies have been
carried out by conjugation of an oligopeptide to AuNPs. Chapter 5 introduces a new
method combining an interfacial strain-promoted azide-alkyne cycloaddition and post
assembly deprotection (SPAAC-PAD) for the well-defined functionalization of small,
water-soluble gold nanoparticles with oligopeptides. This approach will enable the
fabrication of gold nanoparticles with a high degree of complexity with biomolecules for a
variety of applications in targeted cancer diagnosis and therapies.
Keywords
Peptide Nucleic Acids, click chemistry, on-resin, molecular beacon, post-synthetic
modification, magnetic resonance imaging, contrast agent, poly(rA) tail, gold
nanoparticles, peptide.
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10. CHAPTER I: INTRODUCTION

1.1 Preface
The year 2016 witnessed the 25th anniversary of the disclosure of Peptide Nucleic Acid
(PNA). Since the first publication in 1991, PNA has been intensively researched and
extensively exploited due to its unique properties especially in regard to the high nucleic
acid recognition specificity and affinity in binding to complementary sequences. Great
advances in employing PNA for a wide variety of applications in the field of medical
diagnostics, drug discovery, molecular biology and nanotechnology have been made.
1.2 Peptide Nucleic Acid
PNA, an artificial nucleic acid analogue in which the entire sugar phosphate backbone
found in natural nucleic acids, has been replaced with N-(2-aminoethyl)glycine (aeg) units
and was first described by Nielsen et al. in 1991 (Figure 1.1).1 PNA was originally
conceived as a sequence-specific binding reagent targeting the major groove of duplex
DNA to form a triplex. The nucleobases (purines and pyrimidines) are joined to the
backbone by methylene carbonyl linkages. The intramolecular distances and the identity
of the nucleobases are like those in natural nucleic acid molecules. More importantly,
specific hybridization occurs between PNA and DNA or RNA sequences obeying WatsonCrick base pairing rules. The neutral polyamide backbone of PNA leads to binding
complementary nucleic acid strands with higher affinity whereas electrostatic repulsions
occur between the negative phosphate groups on each strand of DNA. Additionally, PNA
hybridizes to DNA or RNA sequences under low salt conditions while cations are needed

1

to counteract the inter-strand repulsion between two negatively charged natural nucleic
acid strands which would hamper duplex formation. Although DNA may depurinate under
acidic conditions, PNA is more stable across a wide range of temperatures and pH values.2
It is also resistant to nucleases and proteases unlike natural nucleic acids.3 All these unique
properties have made PNA advantageous hybridization probes in various applications.
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Figure 1.1 Chemical structures of double-stranded DNA and PNA.
1.3 Synthesis of PNA
The preparation of PNA oligomers is based on standard solid phase peptide synthesis
(SPPS) protocols developed by Merrifield,4 after which two different protection schemes:
tert-butyloxycarbonyl (Boc) and 9-fluorenylmethoxycarbonyl (Fmoc), have been
employed. Although Boc chemistry of PNA has been well developed, the detracting
qualities cannot be neglected such as the repeated use of extremely hazardous and corrosive
TFA that effectively prevents non-chemists from accessing PNA and makes synthesis
onerous. Alternatively, Fmoc-based PNA synthesis has milder deprotection/cleavage
procedure allows for a wider range of labeled molecules to be prepared and provides for
2

simplified final cleavage and deprotection in shorter time. Therefore, Fmoc-based SPPS
has become the most popular synthetic strategy of PNA synthesis.
1.3.1 Fmoc-based SPPS
To apply Fmoc-based SPPS, the protecting group on nucleobases not only needs to be
compatible with Fmoc group, but also needs to be removed readily under cleavage
conditions and render solubility to the resulting monomers. The benzhydryloxycarbonyl
group (Bhoc) has been identified as an appropriate candidate. It allows the PNA monomers
to be maintained at 0.2 M in NMP for weeks and it is completely removed in less than 1
minute in neat TFA, which is convenient for cleavage. Fmoc/Bhoc PNA monomers are
commercially available (Figure 1.2).

Figure 1.2 Standard Fmoc/Bhoc PNA constructs for SPPS.

3

Fmoc-based SPPS consists of repetitive cycles of deprotection, activation-coupling,
capping as well as cleavage and deprotection (Scheme 1.1). Fmoc-based SPPS of PNA is
usually performed on a peptide synthesizer such as Applied Biosystems ABI-433A (Figure
1.3).

Scheme 1.1 Fmoc-based PNA synthesis cycle.

Figure 1.3 Automatic peptide synthesizer [Applied Biosystems ABI-433A].
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The deprotection step of PNA synthesis represents the removal of Fmoc group from the
primary amine of the PNA backbone. It liberates the amine for subsequent coupling of
monomers. Generally, a solution of 20% piperidine in DMF is used for this purpose to
decompose Fmoc group to dibenzofulvene (DBF).
In the coupling step, monomer, base and activator are all required. A solution containing
0.2 M DIPEA and 0.3 M lutidine has been used which proved more effective than 0.5 M
of either base alone in terms of observed side reactions and coupling yields.5 O(Benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) or 1[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium

3-oxid

hexafluorophosphate (HATU) are preferred as the activator for the coupling reaction. The
step of combining solutions of monomer, base as well as activator followed by activation
before exposure to the solid support is challenging on oligonucleotide synthesis platforms.
Therefore, peptide synthesizer which has the same procedure is generally ideal for PNA
synthesis.
The acetylation of oligomer that failed to extend is performed post coupling during each
cycle of the stepwise synthesis. Capping simplifies the purification of the full length PNA
which is highly recommended but not strictly necessary. Capping solution containing 5%
acetic anhydride and 6% lutidine in DMF has been demonstrated a longer shelf life (months
to years) than acetic anhydride and bases such as DIPEA or pyridine in DMF.
PNA may be deprotected and cleaved from the solid support simultaneously by treatment
with TFA/TES (95/5). The use of a scavenger is necessary because the electron rich
aromatic rings of the nucleobases will be alkylated by cations generated by the TFA
treatment. The removal of Bhoc protection is complete within 1 minute, releasing the
5

exocyclic amines of the nucleobases and producing benzhydryl cations, which would be
effectively scavenged by TES. PNA is also cleaved from the solid support with TFA
treatment at the same time and the resulting oligomer is isolated from cleavage mixture by
precipitation with diethyl ether.
Resins for SPPS can generally be used for PNA synthesis. The resin consists of three parts:
base material, linker and anchoring group (Figure 1.4). Various types of resins have been
widely employed depending on base materials: the classic polystyrene (PS) resins,
polyamine resins and TentaGelTM resins which contain polyethylene glycol (PEG) attached
to PS.

Figure 1.4 The composition of resin for SPPS.
Most of the resins are commercially available attached with a variety of different linkers.
Examples of resins with linkers and anchoring groups for SPPS have been shown in Figure
1.5 including Merrifield resin and Wang resin for synthesis of peptide acids, 2-chlorotrityl
chloride resin for synthesis of protected peptide acid, rink amide resin for synthesis of
peptide amide.
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Figure 1.5 Examples of resins for SPPS.
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rink amide resin

Different protocols are required to preload the first monomer to the resins depending on
the anchoring groups. PNA synthesis is optimally performed on resins loaded below 0.2
mmol/g, because PNA quality would be compromised at higher loading due to aggregation
of the extending oligomer during synthesis. Therefore, it is usually necessary to download
the resin before PNA synthesis.
1.4 Chemical modification of the PNA
1.4.1 Nucleobases modifications in PNA
The formation of stable duplex and triplex structures is of great significance in most
applications of PNA. In this context, the modification of nucleobase of PNA monomer is
an effective way to control recognition between nucleic acids strands. Nucleobase
modification of PNA has been comprehensively reviewed by Hudson and coworkers.6 For
example, 5-bromouracil (5-BrU) and 5-methylcytosine (5-MeC) have been found to increase
the stability of both double and triple helices in DNA (Figure 1.6). Furthermore, a common
method for the derivatization of pyrimidine bases, especially uracil, is to take advantage of
transition metal-catalyzed cross-coupling between the halogenated nucleobase and
terminal alkynes using the Castro-Stephens/Sonogashira reaction. Various alkynes could
be used to introduce tethered functional groups. The synthesis of a variety of 5alkynyluracil monomers that are compatible with Boc-based oligomerization chemistry has
been developed. (Figure 1.6)7 However, the incorporation of the 5-alkynyl group only
produced very modest stabilization, as all PNA-DNA chimeras formed complexes of lower
stability than the control DNA:DNA duplex.

7

Figure 1.6 5-Modified pyrimidines. 5-BrU: 5-bromouracil; 5-IU: 5-iodouracil; 5-MeC: 5methylcytosine;
benzylthiopropargyl

5-PAU:

5-(propargyl
ether)uracil;

alcohol)uracil;
2:

1:

5-(p-methoxy-

5-(N-(4,5-dimethoxy-2-

nitrobenzylprogargylcarbamate)uracil; 3: 5-(ferrocenylpropargylcarboxamide)uracil.
To enhance the stability of complexes formed by PNA and target DNA/RNA, nucleobases
with a larger π-surface area for stronger stacking interactions or that are able to make
additional H-bonds or that are positively charged have been prepared (Figure 1.7). A series
of bicyclic thymine analogs (bT) based on the 1,8-napthyridin-2-(1H)-one ring system has
been prepared and evaluated by Nielsen and coworkers (Figure 1.7).8,9 The best
performance in terms of stabilization of duplexes and triplexes was 7-chloro-1,8napthyridin-2(1H)-one (7-Cl-bT). Tricyclic analogs of cytosine have shown better
performance in oligonucleotide chemistry. A tricyclic cytosine analog (tC) has been
reported by Nielsen and coworkers which performs well to be stabilizing in duplex-forming
sequences, especially in contiguous positions or adjacent to purines. The phenoxazine
cytosine analog was used to scaffold a tethered amine that could provide an additional Hbond to its complement. However, it was found to give no or minor stabilization depending
8

on the target. The G-clamp was prepared in order to build in specific, additional bonding
interactions. The G-clamp and propyl-G-clamp led to stabilization while maintaining
excellent sequence discrimination.10 Fmoc/Cbz-protected monomers of the G-clamp and
guanidine G-clamp derivatives have been developed.11 Additionally, Nielson and
coworkers have attempted to retain the benzoyl group (Bz) on the exocyclic amine of
cytosine. The monomer, N4-benzoylcytosine (CBz) is compatible with Boc-oligomerization
chemistry. The incorporation of CBz into poly-pyrimidine PNA sequences would normally
strongly favor triplex formation.

Figure 1.7 Analogues of thymine and cytosine.
1.4.2 Modification of PNA on the backbone
PNA analogues with a modified backbone have also drawn scientists’ attention. The
repeating backbone unit has been extended with a methylene group to either N-(2aminoethyl)-alanine or N-(3-aminopropyl)glycine or propanoic acid unit with the ethylene
carbonyl linker (4, 5, Figure 1.8).12 However, minor importance for the stability of PNA
9

has been observed when an extra methylene group is placed in the backbone. Hyrup et. al.
reported a more flexible backbone containing a secondary amine replacing the secondary
amide (PANA) (6, Figure 1.8).13 After coupling of the nucleobase, the double bond of
secondary amide is oxidised to aldehyde. The PANA oligomer is then obtained on solidphase by reductive amination. Surprisingly, the incorporation of one PANA monomer does
not destabilize the duplex, either.
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Figure 1.8 Some examples of backbone modified PNA monomers.
To overcome the poor solubility issue of PNA in aqueous environment, PNAs with a
constrained trans-4-hydroxy-N-acetylpyrrolidine-2-phosphonate backbone (pHypNAs)
were introduced. (7, Figure 1.8)14 It has been revealed that they have excellent solubility
in water and at the same time preserve biological stability and high hybridization
characteristics of classical PNAs.15,16 These PNA also showed good ability to penetrate cell
membranes together with high antisense activity in a cell-free system, in living cells and in
model organism.
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Oxy-PNA (OPNA) with an ether linkage in the main chain was reported by Kuwahara in
1999. OPNA is chiral with nucleobases attached to the backbone via an ethylene linker.17
8, Figure 1.8) The ether linkage of the backbone improves the solubility of the oligomers
in water. Other chiral PNAs (CPNAs) with modification on the backbone have also been
obtained by incorporation of substituents at either the α- or the γ-position. Comparison of
the effects of substituents at the α-position with those of the γ-position revealed that γmodification is more effective to improve the DNA binding ability.18 Also, PNA monomers
with a methyl group at the β-position have been synthesized.19
Additionally, the attempts of rigidifying the backbone of PNAs have been made avoid the
problem of rotamers that exist around the tertiary amide bond in regular aeg PNAs, thus
obtaining high selectivity in the binding of DNA/RNA (Figure 1.9).

For example,

aminoprolyl (ap), aminoethylprolyl (aep), aminoethylpyrrolidinone (aepone) and
pyrrolidine PNAs have been all synthesized from the same scaffold 4-hydroxyproline.
Cyclopropane (cpr) PNA carries a very rigid 3-member ring. Introduction of methylene
bridging β-C and γ-C of the aminoethyl moiety as in cyclopentyl (cp) and cyclohexyl (ch)
PNAs results in stabilization of DNA and RNA duplexes.
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Figure 1.9 Structures of conformationally rigid PNAs, stereochemistry not shown.
1.4.3 Modification of PNA on the nucleobase-backbone linker
Besides nucleobase modified PNAs and backbone modified PNAs, many linkage-modified
PNA analogues have also been synthesized. For example, the linker to the nucleobase was
extended from methylenecarbonyl to ethylenecarbonyl.12 The thermal stability of the
hybrids between these PNA oligomers and complementary DNA oligonucleotides was
significantly lower than that of the corresponding complexes involving unmodified PNA.
Therefore, the distance between the backbone and the nucleobases plays a major role in the
stability of PNA-DNA hybrids. However, the sequence selectivity was retained.
To understand the role of the nucleobase-backbone linker in the PNA oligomer structure
and in the hybridization process, molecules lacking the tertiary amide bond between the
base and the backbone were synthesised. It has been investigated that the methylene
carbonyl unit was replaced by a flexible ethylene linker (Figure 1.10).20 The amide
functionality in the base-linker unit in PNAs has been found to determine significantly the
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affinity and preferred strand orientation in PNA/DNA duplexes. Nevertheless, OPA offers
the unique possibility to introduce a fourth substituent on the double bond, which could be
of interest for improving binding or solubility properties, or for the attachment of functional
units that may act on bound complementary RNA or DNA.

Figure 1.10 Sections of the chemical structures of deoxyribonucleic acids (DNAs),
polyamide or peptide nucleic acids (PNAs), and (E)- and (Z)-olefinic polyamide nucleic
acids (OPAs)20 (copyright 2000 John Wiley and Sons).
1.4.4 Post-synthetic modification of PNAs and click chemistry
A vast number of modified PNA monomers have been reported to be compatible with
Boc/Fmoc chemistry. However, individual modification of nucleobases in PNA monomers
is always time-consuming and labour intensive. Therefore, post-synthetic functionalization
of the PNA oligomer represents a viable alternative to potentially reduce the overall
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synthetic effort, as well as introducing a step that is amenable to structural diversification
is attractive. In 2001, Ikeda and co-workers synthesized an amino-containing PNA
monomer and successfully functionalized a PNA oligomer through a post-synthetic amide
bond formation.21 Later the Hudson group prepared a PNA monomer containing the methyl
orotate nucleobase which is compatible with Fmoc-based synthesis. Treatment of the resinbound oligomers with hydroxide or amines cleanly converted the ester to an orotic acid or
orotamide-containing PNA.22 Additionally, Seitz reported the introduction of Bocprotected N6-aminoalkyladenine into PNA oligomer. After the removal of the Boc-group,
a fluorescent reporter was post-synthetically attached to the N6-position of adenine.23 More
recently, PNA monomers with an alkynyl or azido group have been developed with the aid
of click chemistry.24,25
Click chemistry was first described by Sharpless and coworkers in 2001.26 It refers to
reactions those are fast and easy to perform, give rise to the intended products in very high
yields with little or no byproducts, work well under many conditions, and are unaffected
by the nature of the groups being connected to each other. A series of click reactions have
been discovered and employed that include copper(I)-catalyzed azide-alkyne cycloaddition
(CuAAC), strain-promoted azide-alkyne cycloaddition (SPAAC), strain-promoted alkynenitrone cycloaddition (SPANC), alkene and azide [3+2] cycloaddition, alkene and tetrazine
inverse-demand Diels-Alder as well as alkene and tetrazole photoclick reaction. Before
long a tremendous number of applications using click reactions emerged among diverse
research areas including nucleic acids, drug discovery, material sciences and
nanotechnology.
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Obviously, click chemistry is also an attractive strategy for modifications of PNA
monomers and/or bioconjugation of oligomers. Kumar and co-workers have reported the
synthesis of peptide-oligonucleotide conjugates by using CuAAC.27 An alkyne-containing
PNA monomer for the facile insertion of one or two organometallic ferrocenyl moieties
into PNA oligomers via CuAAC was reported by Metzler-Nolte and co-workers (9, Figure
1.11).24 Later the same group described the facile N-terminal functionalization of PNA
with azide or alkyne functionalities on the solid phase, and their subsequent conversion by
click chemistry with different alkynyl and azido ferrocene derivatives to yield a small
library of ferrocene-PNA bioconjugates.28 Additionally, two clickable PNA monomers
were reported by Winssinger et al. (10, 11a, 11b, Figure 1.11). PNA fragments may be
assembled by using these monomers via CuAAC. N-propargyl analogues (12a-c, Figure
1.11) were synthesized and used to synthesize PNAs bearing a triazole in lieu of the amide
bond assembled using a “click” cycloaddition.29 An efficient, versatile PNA ligation
method using click chemistry was demonstrated for quantitative conjugation of PNA with
DNA, PNA, or peptide under mild conditions (Figure 1.12).30

Figure 1.11 PNA monomers for click chemistry.
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Figure 1.12 Template-directed click-ligation of PNA-DNA, PNA-PNA (or peptide): (a)
schematic structure and (b) chemical structure at ligation point30 (copyright 2010 John
Wiley and Sons).
More recently Manicardi et al. reported an Fmoc PNA monomer bearing 5azidomethyluracil nucleobase.31 The azide group could be reduced to amine, which was
then coupled with naphthalene-2-carboxylic acid. The azide functional group was also
exploited as reactive tool for the modification of PNA in solution via CuAAC. Similarly,
an azide-containing acpcPNA monomer was synthesized (14, Figure 1.11) and
modification of D-prolyl-2-aminocyclopentane carboxylic acid backbone (acpcPNA) via
CuAAC was investigated.32 Pyrene units could be pre-clicked to the azido acpcPNA
monomer or be post-synthetically attached to PNA oligomers via click reaction. The same
group

also

reported

an
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approach

for

th

e site-specific attachment of fluorophores to the backbone of acpcPNA via reductive
alkylation and sequential reductive alkylation-click chemistry (Figure 1.13).33 Besides, to
explore the potential for utilization of clickable PNAs, Hudson group reported the synthesis
of an azide containing PNA monomer.25 The azide group could be used as a tool for onresin copper catalyzed azide-alkyne Huisgen cycloaddition (CuAAC). At the same time, a
simple approach to modify PNA oligomers by post-synthetic on-resin click chemistry was
described later by us.34 In this way, modification of more than one position of a PNA
oligomer could be performed in a single step and lends itself to divergent syntheses of
modified PNAs. Furthermore, Cγ-substituted azido PNA monomers were synthesized and
inserted into PNA oligomers at specific sites followed by click reaction with propyne
carboxyfluorescein (Figure 1.14).35 The resulting oligomers have been seen by live cell
imaging to accumulate around the nuclear membrane in 3T3 cells.
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Figure 1.13 Illustration of site-specific attachment of fluorophores to the backbone of
acpcPNA via reductive alkylation and sequential reductive alkylation-click chemistry33
(copyright 2013 American Chemical Society).

Figure 1.14 Illustration of click reaction of Cγ-azido PNA monomer with fluorophore and
live cell imaging of the fluorescent oligomers35 (copyright 2014 American Chemical
Society).
Therefore, upon the progress of functionalization of PNAs, success has also been achieved
on the application of click chemistry in the modification of nucleobase, backbone as well
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as linker of PNA. This facile, convenient method has significantly pushed forward the
development of useful targeted PNAs.
1.5 Applications of PNA
As PNA is a powerful molecular tool due to it unique properties and chemistry, extensive
applications have been investigated by using PNA.36–38 Most applications of PNA are
focused on the detection of specific nucleic acids by hybridization,39,40 which has been
widely utilized for gene-related research. It has been demonstrated that PNA is of great use
for developing diagnostic devices, gene detection and therapeutic agents, and nucleic acid
manipulations. In vitro studies indicate that PNAs could inhibit both transcription and
translation of genes to which they have been targeted, thus holding promise for their use
for antigene and antisense therapy.
1.5.1 PNA beacons and fluoroprobes
Molecular beacon (MB) is a single-stranded oligonucleotide molecule containing a stemloop structure labeled with a fluorophore (F) and a quencher (Q) on each end (Figure
1.15).41 It is a powerful probe for selectively detecting DNA and RNA targets. As shown
in Figure 1.15, these probes undergo “off-on” switch with a spontaneous fluorogenic
conformational change when they hybridize to their targets. In addition to the standard
DNA beacon design, a number of PNA beacons have been reported due to the superior
properties of PNA. The application of PNA will be further discussed in chapter II.
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Figure 1.15 Schematic representation of molecular beacon42 (copyright 2006 Nature
Publishing Group).
1.5.2 Single nucleotide polymorphisms (SNPs) detection using PNA
Single Nucleotide Polymorphisms (SNPs) are one of the major sources of genetic variation
in human genome. Numerous diseases such as cystic fibrosis, thalassemia and Alzheimer’s
disease are related to SNPs. The use of PNAs for detections of SNPs has been proved to
be one of the most sensitive approach depending on PNA’s unique hybridization properties
and its great ability to distinguish mismatches of bases.52 Petersen et al. reported a realtime PCR assay for the genotyping of SNPs using short PNA molecular beacons.43 A
method has been described by Ren and coworkers which straightforwardly genotypes SNPs
in dsDNA by matrix-assisted laser desorption/ionization time-of-fight mass spectrometry
(MALDI-TOF MS) in the presence of PNA.44 Rockenbauer et al. demonstrated a simple,
rapid, and robust approach for solid-phase SNP genotyping that combines allele-specific
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hybridization, PNA technology, and flow cytometric detection.45 A strategy employing a
combination of PNA probes, an optically amplifying conjugated polymer (CP), and S1
nuclease enzyme has shown the capability of detecting SNPs in a simple, rapid, and
sensitive manner.46 Bethge et al. reported forced intercalation probes (FIT-probes) in which
an intercalator cyanine dye such as thiazole orange (TO), oxazole yellow (YO),
thiazolopyridine (MO), and oxazolopyridine (JO) serves as a replacement of a canonical
nucleobase. These FIT-probes have shown potential for detection of SNPs (Figure 1.16).47
Interestingly, an electrochemical biosensor has also been developed for the detection of
SNPs using PNA probes. It takes advantage of the significant structural and
physicochemical differences between the full hybrids and SNPs in PNA/DNA and
DNA/DNA duplexes. Ferrocene-conjugated chitosan nanoparticles (Chi-Fc) were used as
the electroactive indicator of hybridization.48 Additionally, a new PNA biosensor has been
reported for electrochemical detection of point mutation in p53 gene corresponding
oligonucleotide based on PNA:double-stranded (ds) DNA triplex formation.49

Figure 1.16 Design principle of FIT-probes. An intercalator fluorophore (F) serves as a
base surrogate and is forced to intercalate adjacent to the expected mutation site. High
fluorescence is only obtained upon formation of matched duplexes47 (copyright 2008
Elsevier).
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A reliable PNA microarray-based method for accurately detecting SNP in human genes
has been described by Mun and coworkers.50 The technique relies on the mismatched
cleavage activity of a single-strand specific (SSS) nuclease. In order to exploit the superior
hybridization properties of PNA with target Human papilloma virus (HPV) DNAs, a novel
PNA array (PANArray HPV) has been developed.51 It enables the detection and genotyping
of HPVs using 32 type-specific PNA capture probes for medically important HPVs. All
tested HPV types showed highly unique hybridization patterns with type-specific PNA
probes. Before long studies were carried out to evaluate PANArrayTM HPV kit for detection
and genotyping of 19 high-risk and 13 low-risk HPV types, and compare it with the
commercially available DNA chip kit genotyping of 24 HPVs.52 The PANArrayTM HPV
test proved to be highly sensitive and accurate even when multiple HPV infections were
present. Then PANArrayTM HPV kit became a popular, commercially available product,
which takes advantage of PNA’s unique properties. In this way, the HPV genotyping can
be completed in a shorter time with smaller DNA samples. In addition, multiple infections
with several HPV genotypes can be precisely identified for diagnosis. Another advantage
is its long shelf life even at room temperature because of chemical stability of PNA.
Tedeschi and coworkers designed and synthesized seven modified PNA probes.53 PNAmicroarrays based on these probes were prepared and applied to SNP discrimination in
model experiments using oligonucleotide mixtures that simulate the different sequences of
the seven tomato varieties. Although the efficiency of binding was somewhat lower than
what is shown by standard PNA arrays, the unsurpassed specificity of the PNA probes still
makes them very promising for the development of PNA-based genotyping methodologies.
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1.5.3 PNA and DNA for Fluorescence In Situ Hybridization
Fluorescence in situ hybridization (FISH) is a cytogenetic technique that uses fluorescent
probes to bind to only those parts of the chromosome with a high degree of sequence
complementarity.54 It is an important molecular assay for determining the number, size
and/or location of specific DNA sequences in mammalian cells, which is developed in the
combination of the microscopy observation and the specificity hybridization of
DNA/rRNA.55 Perry-O’Keefe reported a standard FISH method using PNA probes for
analysis of gram-negative, gram-positive bacteria, as well as yeast. Fluorophore labeled
PNA probes were designed targeting specific rRNA sequences of Escherichia coli,
Pseudomonas aeruginosa, Staphyloccocus aureus, Salmonella as well as eubacteria and
eucarya.56 In addition, a PNA probe (CJE195) was designed and found to bind with higher
affinity to a previously reported low affinity site on the 16S rRNA than the corresponding
DNA probe.55 Huang et al. reported a PNA probe for detection of the toxic dinoflagellate,
Takayama pulchella TPXM, by employing FISH combined with epifluorescent
microscopy and flow cytometry.57 In 2011, Shiraishi and coworkers developed a pair of
biotinylated PNA probes targeting two sequences in 18S rRNA from the parasite
Trypanosoma brucei at a distance of 191 nt (corresponding to maximum distance of ca. 60
nm) from each other.58 It has been shown that by simple fluorescence microscopy analysis,
PNA probes specifically detect the presence of 18S rRNA in a total RNA extract from less
than 300 parasites. Later Zhang et al. reported a PNA-FISH method for detection of
Listeria species (Figure 1.17).59 In silico analysis showed that three PNA probes Lis-16S1, Lm-16S-2 and Liv-16S-5 were capable to specifically identify Listeria genus, Listeria
monocytogenes and Listeria ivanovii, respectively, in comparison with the control probe.
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PNA-FISH method has also been applied in identification of probiotic bacteria such as
Lactobacillus species and Vibrio genus, demonstrated by Machado et al. and Zhang et al.,
respectively.

60,61

To date, PNA FISH tests have been greatly interesting and

commercially available for rapid identification of bacteria and yeast directly from positive
blood cultures. They not only enhance the efficiency of hospitals for appropriate therapy
while avoiding unnecessary use of antibiotic, but also improve patient outcomes as well as
lower hospital costs.62,63

Figure 1.17 Typical PNA hybridization results. (control, top left) Cells of Vibrio flurialis
ATCC 33810 hybridized with the universal probe BacUin. (top right) Cells of L. grayi Li07
hybridized with the Listeria-specific probe Lis-16S-1. (bottom left) Cells of L.
monocytogenes SLCC2755 hybridized with the L. monocytogenes-specific probe Lm-16S-
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2. (bottom right) Cells of L. ivanovii Li01 hybridized with the L. ivanovii-specific probe
Liv-16S-5.59 (copyright 2012 Elsevier)
1.5.4 Antigene and antisense therapy
Antisense technology is a significant approach to inhibit or down-regulate the production
of a target protein by using antisense DNA, RNA and artificial DNA/RNA analogues. An
antisense sequence is an oligonucleotide that is perfectly complementary to the target
nucleotide sequence present in the cell. There are two possible mechanisms for an antisense
effect. The one that relies on targeting of the mRNA is called the antisense strategy. The
other one that is designed to bind to the double-stranded DNA or genes situated in the
nucleus, is called the antigene strategy (Figure 1.18). Whereas the antisense strategy is well
established with several examples of in vitro and in vivo applications,64 the antigene
approach is still in its infancy and the understanding of the involved mechanism is limited.

Figure 1.18 Representation of antisense and antigene strategies.65 (copyright 2002 Royal
Society of Chemistry)
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Earlier studies have shown that the binding of PNA to complementary DNA can efficiently
block transcriptional elongation and inhibit the binding of transcriptional factors. Boffa
and coworkers demonstrated that PNA could invade the CAG triplets of the androgen
receptor (AR) and TATA-binding protein (TBP) genes in human prostatic cancer cells. It
has been shown that the PNAs readily entered the nuclei of lysolecithin-permeabilized cells
and effectively inhibited sense transcription of unique AR and TBP DNA sequences
downstream of the site of PNA:DNA hybridization.66 PNA-mediated inhibition of
transcription was also reported for the alpha-chain of the interleukin-2 receptor.67 Nielsen
et al. have discussed that even an 8-mer PNA can efficiently block transcription by binding
to DNA duplex. 68 Therefore, the antisense potential of duplex-forming and triplex-forming
PNAs has been investigated.

69

It has also been found that PNA interacts with mRNA

independently of the RNA secondary structure. Studies on the mechanisms of antisense
activity have demonstrated that PNA inhibits expression in a different way from regular
antisense DNA/RNA which needs RNase-H mediated degradation of the mRNAoligonucleotide hybrid. Because PNA is not recognized by RNase, its antisense effect acts
through steric interference of either RNA processing (transport into cytoplasm) or
translation (caused by binding to the mRNA).
Not surprisingly, the antisense and antigene properties of PNA has been described as early
as in 1992.

70

It has been shown that PNA or a mixed sequence 15-mer PNA to the

transcribed strand of a G-free transcription cassette caused 90 to 100 percent site-specific
termination of pol II transcription elongation. Mologni et al. reported that three different
regions of the PML/RARα oncogene, including two AUG potential start codons, were
studied as targets of translation inhibition by antisense PNA in a cell-free system.71
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Furthermore, the inhibition of gene expression by peptide nucleic acids (PNAs) inside cells
has also been explored.72 PNA has also been reported to efficiently recognize the RNA
component of human telomerase (hTR) and inhibit enzyme activity with IC50 values in the
picomolar to nanomolar range. 73
An in vivo study has been performed by using PNA to inhibit δ-opioid receptor gene
function.74 However, the progress using PNA for regulation of gene expression was
hampered by the poor cellular uptake of “naked” PNA by live cells. Therefore,
modifications of PNA oligomers were necessary to improve the uptake of PNA in
eukaryotic living cells. For example, PNA coupled to DNA oligomers, to receptor ligands
or to cell penetrating peptides (CPPs), could help deliver PNA into cells.75 Among these
attempts, PNA-CPP conjugates are of great interest since CPPs are rapidly internalized by
mammalian cells. Pooga et al. reported the use of a PNA-peptide conjugate in the
downregulation of the galanin receptor in neuronal cells in culture.76 Additionally, cationic
liposomes have been demonstrated to efficiently complex DNA-PNA hybrid molecules
which effectively improves the in vivo delivery.77
As a hybridization probe, PNA has shown its promise in the above-mentioned applications.
However, the poor cellular uptake and water insolubility of PNA limit its utilization in in
vivo applications.
1.6 Overview
Based on the advantages and development of PNAs, the objective of this research is to
develop functionalized PNAs that can be used in various applications via post-synthetic
click chemistry. Chapter II describes the design and synthesis of quencher-free PNA
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molecular beacons based on solid-phase post-synthetic click chemistry which has been
demonstrated to be versatile and convenient. The prepared stem-loop PNA beacon showed
rapid binding and response to target cystic fibrosis gene sequence.
Chapter III introduces a “click-couple-click” approach for synthesis of conventional PNA
beacons that contain different reporters on each terminus. The current method for the
synthesis of PNA MBs is mostly based on amide formation to attach reporters to PNA
sequences. However, the complicated protection strategies are required to avoid side
reactions as amide formation possibly happens everywhere in PNA oligomers. In this work
we develop a new method based on solid-phase microwave-assisted CuAAC, which allows
fast, convenient preparation of various conventional PNA beacons. One reporter could be
clicked to an azido-containing PNA first followed by coupling of another azide PNA
monomer. A different reporter would be clicked to the resulting PNA to yield a PNA MB.
This method based on “click-couple-click” is chemically selective, robust and efficient. It
is also of great use for screening fluorophore and quencher pairs for PNA MBs.
Chapter IV describes the preparation of a (Gd(III)-DOTA)4-PNA conjugate targeting
poly(A) tail. On-resin CuAAC has been used to conjugate four units of Gd(III)-DOTA to
a PNA oligomer that contains 10 thymine PNA monomers. Hybridization with poly(A) tail
would significantly increase the loading of Gd ions in a microenvironment, thus helping
enhance the contrast of MRI.
Chapter V shows the bioconjugation of an oligopeptide to gold nanoparticles via strainpromoted azide-alkyne cycloaddition via post-assembly deprotection (SPAAC-PAD). This
strategy would be of great use for functionalization of gold nanoparticles with peptides for
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targeted CT imaging. The success of this approach also allows for the functionalization of
AuNPs with PNAs for various applications.
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11. Chapter II: VERSATILE SYNTHESIS OF QUENCHER-FREE
PNA MOLECULAR BEACONS VIA POST-SYNTHETIC
CLICK CHEMISTRY FUNCTIONALIZATION
Chapter 2 has been published as a research paper, and it is reprinted (adapted) with
permission from Xiaoxiao Wang, Robert H. E. Hudson*, ChemBioChem, 2015, 16, 2156–
2161. Copyright 2015 John Wiley and Sons.
2.1 Introduction to PNA-based molecular beacons
First reported by Tyagi and Kramer in 1996, a molecular beacon (MB) is a single-stranded
oligonucleotide molecule containing a stem-loop structure labeled with a fluorophore (F)
and a quencher (Q) on each end.1 MBs are powerful hybridization probes for simple and
rapid detection of specific DNA/RNA sequences. These probes undergo “off-on” switch
with a spontaneous fluorogenic conformational change when they hybridize to their targets.
A typical MB structure consists of a loop, a stem and reporters. The loop is a 18-30 singlestrand region of the MB which is complementary to the target sequence. The stem contains
two short (4-6 nucleotide residues) oligonucleotides that are complementary to each other
to maintain the closed hairpin structure. Reporters represent a fluorophore and a quencher.
Two forms of energy transfer mechanism in MBs have been proposed: dynamic and static
fluorescence quenching.2 Dynamic quenching includes Förster transfer energy transfer
(FRET) and Dexter transfer (collisional quenching or electron-transfer quenching). For
dynamic quenching, the distance between donor and the acceptor needs to be within 20100 Å, as the two moieties move closer, reduced fluorescence intensity will result. The
spectral overlap should be between the donor’s emission and the acceptor’s absorption
spectra. The relative orientation of the donor and acceptor needs to be approximately
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parallel. Static quenching requires formation of an intramolecular dimer with unique
properties, such as unique absorption spectrum or being nonfluorescent.2–5 Therefore,
appropriate contact between the two moieties is necessary for both mechanisms. It is
known that planar aromatic dyes such as phenanthrene and pyrene6 may participate in π-π
stacking, thus prefering a static quenching.
To improve signal-to-background ratio, the choice of fluorophore and quencher pair is
critical. A systematic study of quenching efficiencies for different fluorophore and
quencher pairs has been reported.5 Matching the fluorophore with an effective quencher
can lead to improvements in detection by reducing the background from the MB in the
absence of targets.
DNA-based MBs have become well-known in gene detection, biosensing, bioimaging and
therapy. However, they are very susceptible to nucleolytic degradation during in vitro and
in vivo studies. Thus artificial nucleic acids analogues, such as locked nucleic acid (LNA)
and unlocked nucleic acid (UNA), have been introduced and employed in the applications
of MBs and light-up probes in recent years.7–9 PNA beacons have also been investigated
due to their superior hybridization features, resistance to nucleases and proteases, chemical
robustness, and sequence discrimination.10–12
To date, various PNA MBs have been developed. A summary of conventional PNA
beacons will be presented in chapter III. In the development of MBs, background signal
has always been a critical aspect to consider. On one hand, it could come from the probe
itself, for example, it is very difficult to achieve complete quenching in a conventional MB
and this may result in a significant background signal. On the other hand, it also occurs
from the native fluorescence of many molecular species in the biological environment.
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These issues deteriorate assay sensitivity and compromise probe selectivity, thus
complicating the analysis of small molecules, nucleic acids, and proteins in a complex
sample. Therefore, the challenge to minimize background signal and to tolerate complex
biological sample interference becomes critical. Researchers around the world have
successfully modified and synthesized various MBs to suit their needs. Recently, variation
on the MB theme has been made to improve their function by eliminating false signals,
increasing specificity, and providing enhanced detection limits. Quencher-free molecular
beacons (QF-MBs) are one of the significant modifications of the conventional MB, in
which the quencher moiety has been eliminated. Based on the design, the reported QFMBs can be broadly classified into two different types: mono-labelled QF-MBs and duallabelled QF-MBs. Mono-labelled QF-MBs contain a fluorophore at the middle or end of
the oligonucleotide while dual-labelled MBs contain two fluorophores at the stem or at the
ends. Singly-labeled PNA probes carrying one environmentally sensitive dye, such as
fluorene,13 pyrene14–17 or thiazole orange have been reported.18–20 MBs containing two
pyrene fluorophores are archetype of dual-labelled QF-MBs. (Figure 2.1)21 Compared to
conventional MBs with on/off output patterns, pyrene-based QF-MBs are attractive due to
unambiguous detection of the target by changes in excimer/monomer ratios.21–23 The
excimer complex also results in a long fluorescence lifetime (30-60 ns) of the excited state
of pyrene compared to the auto fluorescence of cellular extracts (~7 ns). In spite of this,
pyrene has been reported to have low quantum yields when attached to biomolecules and
relatively short absorption and emission wavelengths which can suffer from interference
from cellular auto fluorescence.7,24 However, pyrene-modified quencher-free PNA-based
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QF-MBs are not widely described, with only one based on the modified acpcPNA scaffold
reported recently.25

Figure 2.1 Schematic representation of pyrene-based QF-MB, which was dually labeled
with pyrene at the 3’-and 5’-end of single-stranded oligonucleotides with a stem-loop
structure. In the absence of target DNAs, the “closed” stem-loop conformation
predominantly emits excimer fluorescence (green) whereas the MB undergoes a dynamic
conformational change to emit monomer fluorescence (blue) upon hybridization with
target DNAs21 (copyright 2004 American Chemical Society).
2.2 Synthesis of QF-PNA beacons
PNA beacons are usually synthesized by SPPS using standard and modified monomers that
contain a fluorophore or quencher. However, the synthesis of modified monomers is rather
laborious and time-consuming. Often, luminophore-functionalized monomers cannot be
directly introduced into PNA oligomers efficiently due to incompatibility with the chemical
conditions (acidic or basic) of SPPS. Hence, post-synthetic functionalization of the PNA
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oligomer represents a viable alternative to potentially reduce the overall synthetic effort,
as well as introducing a step that is amenable to structural diversification.
Some post-synthetic methodologies for the preparation of modified PNAs have been
reported. For example, in 2001, Ikeda and co-workers synthesized an amino-containing
PNA monomer and successfully functionalized a PNA oligomer through a post-synthetic
amide bond formation.26 Nevertheless, more convenient and selective methods are needed,
because some luminophores are unstable under the coupling conditions, or the conditions
to reveal the amino group concomitantly remove other protecting groups on the oligomer.
In the same year, click chemistry was described by Sharpless and co-workers,27 after which
a tremendous number of applications of click reactions appeared. These reactions are
touted to proceed under mild, simple conditions, being fast, chemoselective, and high
yielding; thus, these are attractive candidates for the post-synthetic functionalization step.
The archetypal click reaction, copper(I)-catalyzed Huisgen azide-alkyne cycloaddition
(CuAAC) yielding the chemically robust 1,4-disubstituted 1,2,3-triazole derivatives,28 was
an obvious starting point for post-synthetic functionalization of PNA.
A number of groups have reported modifications of PNA monomers and/or bioconjugation
of oligomers by using CuAAC.29–31 However, most of those PNA-CuAAC approaches
were performed in solution. Our attention turned to on-resin CuAAC, because it combines
advantages of click chemistry and SPPS in which an excess of reactants can be used and
are easily washed away from the solid support without tedious work up; it is operationally
easy to perform, and often gives quantitative yields.
Herein, a post-synthetic method based on on-resin CuAAC was developed and utilized in
simultaneous functionalization of PNA, which allows the preparation of pyrene-based
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PNA beacons more efficient. Two pyrene-based PNA beacons, MB1 and MB2, were
successfully synthesized and evaluated.
2.3 Results and discussion
To apply post-synthetic click chemistry to developing PNA MBs, we designed and
synthesized an azide PNA monomer in which a nucleobase was replaced with an azide
group31 (Scheme 2.1). One or more azide monomers can be inserted into a PNA sequence
by automated SPPS in any position without concern for incompatibility.

Scheme 2.1 Synthesis of azide PNA monomer (1).
In the work of this chapter, two azide-containing PNA sequences (PNA1-Az and PNA2Az) have been synthesized via Fmoc SPPS protocol targeting cystic fibrosis (CF), is
agenetic disease caused by loss or mutation of the cystic fibrosis transmembrane
conductance regulator (CFTR) gene (Table 2.1). Then the simultaneous modification of
PNA1-Az for preparation of pyrene-based QF-MBs by post-synthetic on-resin click
chemistry was performed (Scheme 2.2). Directly after oligomer synthesis, the resin-bound
PNA was subjected to CuAAC in the presence of excess 1-ethynylpyrene. The excess
reagents, solvents, and catalyst were easily washed from the resin, whereas the workup to
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remove these materials can be laborious in solution-based methods. After cleavage of the
oligomer from the resin, only the usual HPLC purification was required. By using this
method, a stemless PNA beacon, MB1, was successfully prepared and characterized. Seitz
and co-workers first demonstrated that PNA molecular beacon constructs do not require
the stem-loop structure that is obligate for DNA MBs.13 However, it is conceivable that the
sequence and identity of the fluorophores might impact the degree of interaction, especially
in this example, where both proximity and orientation are important in order for the pyrene
units to effectively π-π stack (excimer formation). Therefore, stem-loop MB2 was
designed and synthesized by using the same method.
Shown in Scheme 2.2, azide-containing PNA oligomers (PNA1-Az, PNA2-Az) were
synthesized by using an azide monomer with automated Fmoc SPPS protocols. Two
conditions for solid-phase CuAAC have been developed. For condition a, CuI was used as
the catalyst, and DIPEA was employed to help dissolve copper in the solvent. The resin
was shaken in the mixture at room temperature under N2. Reaction progress was monitored
by ESI-MS. The click reaction was observed to be complete after two days. As CuI is not
stable in the presence of air or moisture, the more robust catalyst system of CuSO4·5H2O,
along with a reducing agent, sodium ascorbate, was employed for condition b and
stabilized

by

N,N’-dimethylethylenediamine

(DMEDA).

A

mixture

of

isopropanol/DMSO/H2O (1:1:2, v/v/v) was used as the solvent. The resin was shaken in the
aqueous solution at room temperature under N2, and the reaction was deemed complete via
mass spectrometry after 16 h. The excess reactants and copper complexes were then
removed by sequentially washing the resin with DMF, CH2Cl2, H2O, MeOH, and DCM.
After Fmoc deprotection and resin cleavage, the pyrene-based PNA beacons were purified
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by standard HPLC methods. Characterization of the oligomers was carried out by ESI-MS,
which showed that two units of pyrene were simultaneously clicked to the PNA oligomer
quantitatively on the solid support. The resulting oligomers, MB1 and MB2, have been
characterized by ESI-MS. The peaks corresponding to full-length, fully modified
oligomers were observed while the mass of “unclicked” sequences were not detected.
Table 2.1 Oligomers investigated in this study.
Name

Sequence (5'-3' or N-C)*

PNA1-Az

K-Az-CTTTCCT T CACTGT-Az-K

MB1

K-Py-CTTTCCT T CACTGT-Py-K

PNA2-Az

K-CAT-Az-CTTTCCT C CACTG-Az-ATG-K

MB2

K-CAT-Py-CTTTCCT C CACTG-Py-ATG-K

PNA-Ir

K-Ir-CTTTCCT T CACTGT-Ir-K

CF-A

ACAGTG A AGGAAAG

CF-T

ACAGTG T AGGAAAG

CF-G

ACAGTG G AGGAAAG

CF-C

ACAGTG C AGGAAAG

*The complementary of mismatched are underlined.
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Scheme 2.2 General synthesis of PNA MBs by on-resin CuAAC. a) 1-ethynylpyrene (20
equiv.), CuI (200 equiv.), DIPEA (300 equiv.), THF/pyridine (5:3, v/v); b) 1-ethynypyrene
(15 equiv.), CuSO4⋅5H2O (30 equiv.), sodium ascorbate (120 equiv.), DMEDA (60 equiv.),
isopropanol/DMSO/H2O (1:1:2, v/v/v); c) 20% piperidine/DMF followed by TFA/TES
(95:5, v/v).
The easily accessible azide PNA monomer has the potential to facilitate screening of
various PNA constructs. For example, in this work, the resin-bound azide containing PNA
oligomers (5 µmol synthesis scale) was split into several portions used for various click
reactions. Thus, without the need to repeat PNA synthesis, different conditions to optimize
the chemistry for the click reaction were tested. Moreover, different fluorophore alkynes
could be employed to produce varied PNA probes with similar ease while the traditional
method requires onerous labour and a relatively large amount of each fluorophorecontaining PNA monomer.
The stability of the PNA:DNA duplexes was determined by thermal denaturation studies
after annealing of PNA beacons MB1 and MB2 to the perfectly matched or one-base
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mismatched (MM) DNA target strands. The Tm values (Table 2.2) show that the matched
duplex of MB1 demonstrated somewhat typical discrimination over single-MM targets
(∆Tm=6-9 ºC), whereas the single-stranded MB1 did not display a melt transition. On the
other hand, MB2, designed with a stem-loop structure of four PNA base pairs and two
intercalated pyrene units showed an intramolecular Tm that was comparable to its fully
matched duplex with DNA. This demonstrates that PNA:PNA hybridization is extremely
stable, and an even shorter stem for PNA MBs should be considered to ensure that the
stem-loop structure would be disrupted upon hybridization with complementary DNA.
Interestingly, thermal denaturation studies of MB2 and MM-DNAs showed biphasic
melting profiles. This might be due to a mixture of single-stranded (SS) PNA and
PNA:MM-DNA duplex existing together under the experimental conditions.
Thermal denaturation studies were also carried out to determine the stability of PNA
MB2:CF RNA duplexes (Table 2.2). The PNA:RNA duplexes showed greater thermal
stability than the same DNA sequences, yet the discrimination for mismatches remained
the same (∆Tm=8-10 ºC). Interestingly, the UV melt curves with RNA were monophasic.
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Table 2.2 Thermal stabilities and switching ratios of duplexes.
Oligomers[a]

Φ[b]

B[c]

SR[d]

Tm (ºC)

MB1

0.05

2750

--

n.d.

MB1+ matched DNA

0.06

4540

1.3

59

MB1 + MM-T DNA

0.09

5090

2.2

51

MB1 + MM-G DNA

0.1

5690

1.6

53

MB1 + MM-C DNA

0.1

5110

1.7

50

MB2

0.12

5630

--

60

MB2 + matched DNA

0.07

3030

4.5

59

MB2 + MM-A DNA

0.04

2240

3.2

46 & 63[e]

MB2 + MM-T DNA

0.04

2600

3.6

48 & 61[e]

MB2 + MM-C DNA

0.04

2640

3.5

48 & 64[e]

MB2 + matched RNA

0.1

2930

6.4

71

MB2 + MM-A RNA

0.09

2970

5.7

63

MB2 + MM-T RNA

0.1

3000

5.6

61

MB2 + MM-C RNA

0.09

4400

5.4

62

[a] Annealed samples; [b] Quantum yield (0.546 for quinine sulphate in 0.5 M
H2SO4

as

standard

[c]

Brightness

(QY×ε356).

[d]

Switching

ratio

(F397/F475)ds/(F397/F475)ss; [e] Biphasic melting curves.

It is noteworthy that all mismatched duplexes were stable at room temperature (Tm
values >25 ºC), indicating that optimum discrimination of mismatched targets could only
be achieved at a higher temperature. For DNA-based systems, the melting temperatures
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were much more sensitive to ionic conditions, which can be manipulated to provide assay
stringency, whereas PNA hybridization is much less affected by ionic conditions.
To evaluate the ability of pyrene-labeled PNAs to act as molecular beacons, their
fluorescence emission spectra were recorded in the absence or presence of DNA target
strands. As shown in Figure 2.2a, broad emission centred at about 475 nm (black squares)
indicated excimer emission from SS-MB1.The two shorter wavelength emission bands at
385 and 401 nm represent monomer fluorescence. As expected, only monomer emission
was observed when MB1 was hybridized to a DNA target. The colour change could be
readily detected (Figure 2.3). However, the change in excimer/monomer ratios was modest.
The fluorescence spectra of one-base mismatched duplexes with MB1 were also recorded,
and the switching ratio (SR), a parameter for judging discrimination, was calculated for all
duplexes (Table 2.2). The perfectly matched duplex (Table 2.2) had an SR of only 1.3; the
SRs of MM duplexes are higher, thus indicating that MB1 cannot satisfactorily
discriminate fully matched targets from mismatched targets at room temperature. We
hypothesized that the stemless MB1 conformation does not sufficiently favour excimer
formation; thus, in this construct, a stem-loop structure might be necessary to bias pyrene
excimer formation.
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Figure 2.2 Fluorescence spectra of a) MB1 and b) MB2 in the presence of matched DNA.
Conditions: 2 µM PNA and target in 100 mM NaCl, 10 mM NaH2PO4, 0.1 mM EDTA, pH
7, 25 ºC. Excitation: λex = 345 nm.

Figure 2.3 Fluorescence images at individual strand concentration of 2 µM under
illumination at λ=365 nm. a) Left, MB1; right, MB1 + matched DNA; b) Left, MB2; right,
MB2 + matched DNA.
MB2 exhibited higher fluorescence efficiency than MB1 in terms of its better quantum
yield (0.12 vs. 0.05) and brightness (5630 vs. 2750). More importantly, the fluorescence
emission of stem-loop MB2 is shown in Figure 2.2b. Prominent emission at 475 nm
indicated excimer emission, along with the shorter wavelength emission peaks due to the
fraction of the population of molecular beacons that possess pyrenes as discrete monomers.
Likely, the stacking of pyrene chromophores in the stem region of MB2 is partly
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responsible for the excimer emission of MB2 being recorded as a shoulder instead of as a
discrete band. The addition of target DNA caused a significant decrease in the fluorescence
intensity at 475 nm, indicating the disappearance of excimer. It was observed that the
monomer emission of the duplex decreased as well in terms of lower quantum yields and
brightness, implying a quenching phenomenon.32 The origin of the quenching is likely due
to the adjacent GC base pairs in the sequence of the MB2:DNA duplex. Nevertheless, the
change in fluorescence of MB2 before and after hybridization with target DNA is obvious
at room temperature (Figure 2.3b). In contrast to the stemless MB construct, when MB2
was challenged with the perfectly matched complement, an SR of 4.5 was observed (Table
2.2), as well as better fluorimetric discrimination of one-base mismatched targets
(∆SR=0.9-1.3). Moreover, MB2:matched RNA showed the best switch (SR 6.4) and better
discrimination of mismatched targets (∆SR=0.7-1). However, the change in
excimer/monomer ratios of MB2 was not as pronounced as that reported for stemless MB
based

on

pyrene-modified

acpcPNA

(SR

from

1.1

to

30.8).33

Therefore,

fluorescence/melting studies were performed to help us understand the relatively poor
discrimination of PNA:matched duplexes over one-base mismatched duplexes (Figure 2.4).
It was observed that all matched and one-base mismatched duplexes showed similar
excimer emission at 25 ºC and ideal differences among SS, matched duplex, and MM
duplexes at around 50 ºC. This indicates the best discrimination would be achieved when
fluorescence studies of MB2 are performed at 50 ºC instead of at room temperature.
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Figure 2.4 Fluorescence-melting spectra of PNA MB2 in the presence of DNA targets
monitored at 475 nm. λex = 345 nm.
The formation of PNA:DNA helical structure was investigated by circular dichroism
measurements. Without the target, MB2 characteristically showed no CD signal (Figure
2.5). In the presence of a fully matched DNA target, the duplex of MB2 displayed a positive
Cotton effect at 264 nm, a shoulder at 275 nm, and a positive peak at 220 nm. Similar
spectral features of one-base MM duplexes were observed and produced weaker CD
signals than the fully matched duplex. This confirmed that MB2 could form helical
structures with complementary DNAs.
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Figure 2.5 CD spectra of MB2 in the presence of DNA targets. Conditions: 2 µM PNA
and target strands in 100 mM NaCl, 10 mM NaH2PO4, 0.1 mM EDTA, pH 7, 25 ºC.
To judge the hybridization kinetics of MB2, time-dependent fluorescence studies were
carried out. As shown in Figure 2.6, the fluorescence intensity that represented the change
in excimer/monomer ratios reached ~87% of the maximum readout within 1 min after the
addition of fully matched target DNA. This showed the ability of MB2 to rapidly bind
DNA without an annealing step.
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Figure 2.6 Time-dependent fluorescence readout of MB2 with addition of target DNA
(relative emission intensity = the difference between monomer emission intensity at 397
nm and excimer emission intensity at 475 nm). Conditions: 2 µM PNA and target in 100
mM NaCl, 10 mM NaH2PO4, 0.1 mM EDTA, pH 7, 25 ºC. λex = 345 nm.
The target-response curve shown in Figure 2.7 was measured by fluorescence titration
under in vivo-like conditions. With the addition of 0-1.2 equiv. of target into a solution of
2 µm MB2, the change in excimer/monomer ratios (F397-F475) was increased and reached
a maximum at around 1 equiv. The excess target led to no further spectral changes.
Furthermore, target titration studies suggested that the matched CF gene could be detected
at 320 nM at the maximum change in excimer/monomer ratios when MB2 was used as the
probe.
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Figure 2.7 The target-response curve of MB2 with the increase of target concentration
(relative emission intensity = the difference between monomer emission intensity at 397
nm and excimer emission intensity at 475 nm). Conditions: 2 µM PNA in 100 mM NaCl,
10 mM NaH2PO4, 0.1 mM EDTA, pH 7, 25 ºC. λex = 345 nm. Limit of detection (LOD)
was calculated as 320 nM.
To test the versatility of this method, the insertion of two iridium complex moieties into a
PNA sequence by on-resin CuAAC was demonstrated in this work (Scheme 2.3).
Characterization of the oligomer PNA-Ir by ESI-MS showed that two units of iridium
complexes were successfully incorporated into the PNA oligomer quantitatively on the
solid support (Table 2.3). This is in addition to our demonstration of successful insertion
of single fluorenyl and pyrenyl moieties, as well as a dual pyridyl-modified PNA.31
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Ir

Ir

Ir

Ir

Scheme 2.3 Synthesis of PNA-Ir via on-resin CuAAC. (i) Iridium complex (20 equiv.),
CuI (200 equiv.), DIPEA (300 equiv.), THF/pyridine 5:3 (v/v) (ii) 20% piperidine/DMF
followed by TFA/TES 95:5 (v/v).
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Table 2.3 ESI-MS data of PNA sequences in this study.[a]
Sequence
PNA

Found m/z

Calc. m/z

[M+H]+

[M+H]+

1-Az

K-Az-CTTTCCTTCACTGT-Az-K

4547.87

4547.89

MB1

K-Py-CTTTCCTTCACTGT-Py-K

4776.90

4776.97

2-Az

K-CAT-Az-CTTTCCTCCACTG-Az-ATG-K

5891.08

5890.42

MB2

K-CAT-Py-CTTTCCTCCACTG-Py-ATG-K

6121.45

6120.51

PNA-

K-Ir-CTTTCCTTCACTGT-Ir-K
5683.79

5683.14

Ir

[a] Az = Azide monomer, Py = triazole-linked pyrene monomer.
2.4 Conclusion
In summary, we have proposed a versatile and convenient method to develop new PNA
molecular beacons by using on-resin click chemistry. The modification of more than one
position of a PNA oligomer could be performed in a single step and lends itself to divergent
syntheses of modified PNAs. Two quencher-free PNA beacons were designed and
synthesized by using this method, and their properties were investigated. (Figure 2.8)
Compared with stemless beacon MB1, stem-loop beacon MB2 showed better
discrimination upon hybridization with target sequences based on changes in
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excimer/monomer ratios, indicating that the stem region is necessary in the design of PNA
MBs due to the variable interactions between pyrene and neighboring base sequences.
Under in vivo-like conditions, MB2 showed rapid binding and response to target DNA.
However, to achieve an excimer-monomer switching ratio as high as the previously
reported pyrene-based MBs, further modification of MB2 is still need.

Figure 2.8 Top: PNA sequences used for the molecular beacons, MB1 and MB2,
illustrating the placement of the pyrene monomer (X). N' = N-terminus, C' = C-terminus,
K = L-lysine, target sequence underlined. Bottom: Conceptual representation of stemless
and stem-loop PNA beacons and their response.
2.5 Experimental
Synthesis of PNA sequences (PNA1-Az, PNA2-Az)
PNA synthesis was performed on a 5 µmol scale using an automated ABI 433a peptide
synthesizer. TGR Tentagel R-Lys(Boc)-Fmoc resin (loading 0.045 mmol/g) and PEGA56

Lys(Boc)-Fmoc resin (loading 0.113 mmol/g) were used for condition a and condition b,
respectively. The synthesis was terminated without the final Fmoc deprotection. A small
portion of the resin was taken for characterization and the oligomer was
cleaved/deprotected under standard conditions for the characterization of PNA1-Az and
PNA2-Az by ESI-MS. Other portions of the resin were taken and manipulated in manual
peptide synthesis vessels.

General procedure for on-resin click chemistry
Condition a: The resin with PNA-Az was placed in THF:pyridine (5:3) (0.8 mL) in a
peptide synthesis vessel. 1-Ethynyl pyrene (20 equiv.), CuI (200 equiv.), DIPEA (300
equiv.) were added to the resin successively. The resin was shaken in the mixture at room
temperature under N2 for 2 days. After the reaction was deemed complete by Waters LCT
Premier ESI-MS, the solvent was drained and the resin was washed sequentially with DMF,
DCM, H2O, MeOH and finally DCM.

Condition b: 1-Ethynylpyrene (15 equiv.) in isopropanol: DMSO (1:1) (0.5 mL),
CuSO4·5H2O (30 equiv.) in H2O (0.5 mL), NaAscorbate (120 equiv.) in H2O (0.5 mL) and
DMEDA (60 equiv.) were added to the resin in a peptide vessel. The resin was shaken at
room temperature under N2 overnight. After the reaction was deemed completed by ESIMS, the solvent was drained and the resin was washed sequentially with DMF, DCM, H2O,
MeOH and finally DCM.
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After condition a or b, the resin was shaken in 2 mL 20% piperidine/DMF for 15 min to
remove the fmoc protecting group. Then PNA was cleaved, purified and characterized
following by our previously reported procedure.34

Quantification of PNA oligomers
UV-visible spectrophotometer was used to determine the concentrations of PNA solutions.
10 µL of stock PNA sample was diluted to 1 mL for quantification and the absorbance at
260 nm of the sample was measured. 13700, 8800, 6600, 11700 and 2840016 M-1cm-1 were
used as ε260 values of A, T, G, C and the pyrene-modified monomer, respectively. The
equation below was used for calculation.
c (µM)=

13.7NA

1000×A260
8.8NT 11.7NG 6.6NC

28.4Npy

Thermal denaturation experiments of oligomers
UV melting experiments were carried out to measure the Tm values of oligomers in this
study using the following ionic conditions: 100 mM NaCl, 10 mM Na2HPO4, 0.1 mM
EDTA, pH 7.0. Samples at 2 µM concentration were heated to 95 ºC, cooled to room
temperature over 1-2 hours, and placed at 4 ºC overnight. Denaturation was performed
from 15 to 90 ºC at a temperature ramp rate of 0.5 ºC/min. The Tm values are an average
of three measurements and are rounded to the nearest 1 ºC. The error in Tm values was ±
0.9 ºC. Tm values were estimated for cooperative transitions by the first derivative method.
Temperature dependent UV spectra that lacked upper and lower baselines, lacked
sigmoidal shape or were indistinguishable from SS PNA intramolecular melting were
deemed not be to cooperative transitions.
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Fluorescence studies of oligomers
Samples for all fluorescence studies were prepared in a quartz cell (path length: 1 cm) in
the same ionic conditions as for the denaturation experiments. Parameters for fluorescence
spectra are: excitation wavelength, 345 nm; scanning range, 350-600 nm; data interval, 0.1
nm; scan rate: 1 nm/s; temperature, 25 ºC. Fluorescence denaturation was performed from
20 to 80 ºC at a temperature ramp rate of 0.5 ºC/min.

In the target titration fluorescence studies, a series of solutions containing the
corresponding DNA target (0.2, 0.4, 0.6, 0.8, 1.0, 1.2, 1.4, 1.6, 1.8, 2.0, 2.2, 2.4 µM) were
mixed with MB2 (2 µM). The LOD value was defined as the lowest concentration of the
target in a series detected at the corresponding maximum change in excimer-monomer
ratios such that the fluorescence signal to noise ratio (S/N) relative to the blank solution of
a medium salt buffer was ≥3. 8,32

Calculation of photophysical properties
For calculation of quantum yield (QY), quinine sulfate in 0.5 M H2SO4 (Φ = 0.546,
excitation at 355 nm) was used as standard material.7 The QYs of MB1, MB2 and their
duplexes were calculated according to a previous report.8 Absorbance at 356 nm was
measured and used for excitation of the oligomers. Refractive indices were 1.333. For
calculation of extinction coefficients of oligonucleotides, Beer–Lambert law (A = ε l c, l:
1 cm, c: 2 µM) was used. The brightness was expressed by QY × ε356.
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CD studies of oligomers
CD spectra where measured under the same conditions of concentration and ionic strength
as for denaturation experiments. Cuvette path length was 1 mm and scans were made from
400-200 nm at a rate of 100 nm/min with a data pitch of 0.5 nm and response time of 0.5
sec. Scans were averaged over 10 accumulations and are presented molar ellipticity
(deg·cm2·dmol-1). Savitzky-Golay smoothing method was used.
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2.6 Supplementary Information

Figure 2.9 ESI-MS spectra of 1-Az; calculated mass for C188H245N82O56: 1137.7289
[M+4H] 4+ (top), 910.3847 [M+5H] 5+ (bottom).

61

Figure 2.10 ESI-MS spectra of MB1 calculated mass for C209H254N82O54: 1194.9991
[M+4H] 4+ (top), 956.2008 [M+5H] 5+ (bottom).
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Figure 2.11 ESI-MS spectra of PNA 2-Az; calculated mass for C241H309N113O69:
1179.5729 [M+5H] 5+ (top), 983.1454 [M+6H] 6+ (bottom).
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Figure 2.12 ESI-MS spectra of MB2; calculated mass for C262H319N113O67: 1225.6352
[M+5H]5+ (top), 1021.5307 [M+6H]6+ (bottom).
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Figure 2.13 ESI-MS spectra of PNA-Ir; calculated mass for C241H282Ir2N90O54: 1137.4338
[M+5H]5+ (top), 948.0295 [M+6H]6+ (bottom);
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Figure 2.14 HPLC-UV absorption spectra of PNA at 265 nm. (a) MB1; (b) MB2.
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12. CHAPTER III: SYNTHESIS OF CONVENTIONAL PNA
MOLECULAR BEACONS VIA A CONVENIENT “CLICKCOUPLE-CLICK” APPROACH
3.1 Introduction to conventional PNA beacons
The significance of molecular beacon (MB) technology was discussed in Chapter II. The
focus of this chapter is on the development of synthetic strategies for conventional PNA
beacons. The first PNA-based MB that contained a PNA probe domain and a hybrid PNADNA stem was developed by Lizardi and co-workers in 1998 (Figure 3.1).1 The reporter
groups used in this study were 7-amino-4-methylcoumarin-3-acetic acid (AMCA) as the
fluorophore and p-(dimethylaminophenylazo)benzoic acid (DABCYL) as the quencher.
The synthetic scheme shows that DABCYL-succinimidyl ester was coupled to the DNA
sequence which possessed an aminated thymidine by formation of a stable carboxamide.
The AMCA was coupled to the amino group of glycine on PNA strand via the same
reaction (Scheme 3.1). Then the modified DNA and PNA were conjugated by formation
of disulfide. It has been found that this probe undergoes a fluorescent change in the
presence of a complementary DNA target.
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Figure 3.1 Structure and sequence of the first PNA-DNA molecular beacon1 (copyright
1998 Elsevier).
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Scheme 3.1 Synthetic scheme of first PNA-based MB1 (copyright 1998 Elsevier).
Before long the synthesis of PNA MBs based on solid-phase peptide synthesis was
investigated and disclosed. Different from conventional DNA MB constructs which
contain a stem-loop structure, PNA MBs are usually stemless, due to the tendency of PNA
to form secondary structures that results in the appended FRET pair (usually at opposite
termini) being in close proximity. For example, Seitz reported a stemless PNA molecular
beacon in 2000.2 SPPS of PNA was performed by using a hydroxycrotyl-oligoethylene
glycol-n-alkanoyl (HYCRON) anchor on the solid support,3 which is stable under acid- or
base-deprotection protocols (Scheme 3.2). The protection groups of the nucleobases on the
resin-bound PNA were then removed, followed by treatment with DABCYLhydroxysuccinimide ester (SE) in order to attach the quencher to PNA via amide formation.
However, the unprotected thiol groups were found to readily form disulfide. Thus, a
dithiothreitol reduction was used in order to liberate the thiol groups, to which the 5-(2aminoethylamino)1-naphthalene sulfonic acid (EDANS) group was attached by a selective
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alkylation with 5-(2’-iodoacetamidoethyl)aminonaphthalene sulfonic acid (IAEDANS).
Finally, the resin was cleaved by using a Pd0-catalyzing allyl transfer with morpholine
scavenger. The resulting PNA beacon was demonstrated to fluoresce weakly in the singlestrand state, but showed a vivid fluorescence enhancement after hybridization with a
complementary oligonucleotide.

Scheme 3.2 Solid-phase synthesis of doubly labeled PNA as probes2 (copyright 2000 John
Wiley and Sons).
Kitagawa et al. also described the synthesis of a PNA MB in 2002.4 They first prepared a
DABCYL-containing PNA monomer and incorporate it into PNA oligomers via Boc-based
SPPS. However, the DABCYL moiety decomposed during the step of cleaving MBHA
resin using a TFMSA/TFA solvent system. Therefore, they started to consider a postsynthetic method to introduce DABCYL into the PNA oligomer. Fmoc/Cbz-protected
resin-bound PNA was prepared and treated with piperidine to remove Fmoc group but
retain Cbz groups on all nucleotides as well as the C-lysine. The fluorescein moiety could
then be coupled to PNA. Subsequently, the removal of Cbz group was accomplished
followed by attachment of DABCYL to PNA. The conjugation of both fluorescein and
DABCYL is achieved via amide formation.
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Due to the desirable and useful properties of PNA, PNA MBs have become commercially
available and the applications of PNA MBs have been extensively investigated.5–12 In some
studies, the fluorophore and quencher were conjugated to PNA oligomers either via the εamino group of Lys or the N’-amino group of Glu (e.g., fluorescein-EGCTGCCTCCCGTAGGA-K-K-DABCYL). Success was achieved by using PNA to
detect and quantify rRNA in solution.8 Additionally, PNA MB was able to quantify 16S
rRNA of specific populations in RNA extracts of environmental samples for the genera
Dechloromonas and Dechlorosoma.9 Petersen et al. reported that short PNA beacons are
effective for real-time PCR allelic discrimination of SNP.10 PNA MB was also
demonstrated useful for the detection of PCR amplicons in droplet-based microfluidic
devices.11 Two stemless PNA beacons were synthesized later by Totsingan et al. for the
detection of full-matched or single mismatched DNA and showed high mismatch
recognition via ion exchange HPLC.12
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Scheme 3.3 Synthesis of FIT probes using Thiazole Orange (TO) as a Fluorescent Base in
PNAs13 (copyright 2005 John Wiley and Sons).
In 2005, Seitz et al. developed FIT (forced intercalation) PNA fluorescent probes to
distinguish single-base mutation under non-stringent hybridization condition.5,13–15 These
PNA probes were demonstrated sensitive hybridization probes with outstanding
fluorescence enhancements upon hybridization. In the original FIT probes, the intercalator
dye thiazole orange (TO) serves as a base surrogate. The TO fluorophore was first equipped
with carboxyalkyl spacers of varying length in order to enable coupling with the PNA
backbone (Scheme 3.3). As the central building block, an orthogonally protected backbone,
Fmoc/Aloc-protected aminoethylglycine was incorporated during the Fmoc-based PNA
SPPS. However, the coupling of TO moiety with the backbone that contains one free amino
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group was unsuccessful due to the poor solubility of TO derivatives and low reactivity of
the N-alkyl amino acid structure in oligomer 4. Ultimately, pyridinium p-toluenesulfonate
was found to help increase the solubility of TO and enable the coupling with resin-bound
PNA oligomer 4. FIT probes were further modified by adding an additional Lys conjugated
with a fluorophore on the N-terminus as stemless PNA beacons (Figure 3.2).14,16 The shift
of the emission wavelength from the intercalator dye to the near infrared dye with high
sensitivity and specificity at nonstringent conditions has been observed, which may be
useful for reducing background

Figure 3.2 Comparison of A) DNA molecular beacons with B) stemless FIT- PNA beacons
in the detection of complementary nucleic acids. In stemless FIT-PNA beacons, an
intercalator dye such as thiazole orange (TO) serves as a base surrogate that signals
stacking against matched base pairs by FRET to a near infrared dye such as NIR667.
PNAs.14 (copyright 2008 John Wiley and Sons)
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in single-base-mutation analyses and in live-cell RNA imaging. Similarly, a thiazole
orange modified PNA MB (TO-PNA-MB) was reported by Yavin et al. and demonstrated
effective to detect endogenous K-ras mRNA in living cells at a single base resolution.17
Although useful PNA MBs have been synthesized and have shown promise in various
applications, the limitations of the conventional methods for functionalization of PNA
cannot be neglected. Synthesis of a luminophore-containing PNA monomer is always
tedious and labour-intensive. Insertion into a PNA sequence requires a large amount of
precious modified monomer. Moreover, some modified PNA monomers are not
compatible with SPPS or coupling yield is poor. Thus post-synthetic functionalization has
been attempted. However, the current approach is still based on the “deprotectioncoupling-deprotection-coupling” scheme, which is obviously not optimum. In order to
achieve orthogonal functionalization, different protecting strategies are necessary, in which
the conditions to remove the various protecting groups and the conditions to cleave the
resin are usually complicated or harsh, making the procedure difficult to operate. Moreover,
some fluorophores or quenchers are insoluble or unstable under coupling conditions.
Additionally, it is still tedious and not very chemo-selective. Minor change of the substrates,
solvents or reaction conditions would lead to failure of the whole process or low yields.
Therefore, more robust and higher chemically selective post-synthetic methods are needed
for developing PNA MBs. Copper-catalyzed click chemistry is obviously one of the most
promising choices. My attention turned to on-resin CuAAC resulting in successful results
of preparation of pyrene-based quencher-free PNA MBs (Chapter 2). However, to the best
of our knowledge, click chemistry has not been applied in the development of conventional
PNA beacons which contain different reporters. Hence, in this chapter a “click-couple-
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click” post-synthetic approach, which is based on microwave-assisted on-resin CuAAC for
divergent synthesis of conventional PNA beacons is described. This approach has the
potential to significantly simplify the procedure of sequentially attaching fluorophore and
quencher to PNA oligomers. It may also facilitate the screening of fluorophores or
quenchers in the development of most effective PNA MBs.
3.2 Results and discussion
An azide monomer has been designed and synthesized in which a nucleobase was replaced
with an azide group.18 It was incorporated into a PNA sequence by automated SPPS in the
position close to C-terminus. DABCYL, the quencher used in this study, could be attached
to PNA oligomer via microwave-assisted on-resin CuAAC followed by coupling reaction
of an additional azide monomer to PNA. To improve the efficiency of on-resin CuAAC,
another chelator ligand, tris(3-hydroxypropyltriazolylmethyl)amine (THPTA), was used in
this study.19,20 The use of THPTA reduces the tendency for copper(I) species to aggregate,
while the kinetically labile triazolyl-copper binding allows rapid ligand exchange
providing the alkyne and azide substrates with access to the copper center. In addition, the
3-hydroxypropyl group of THPTA enhances the aqueous solubility of the ligand which is
desired in our click conditions. Moreover, the use of THPTA facilitate the removal of
copper from the resin, which is crucial for the next step of coupling reaction. The
functionalized PNA was subjected to Fmoc deprotection and capping on the N-terminus.
A fluorophore-containing alkyne would be then clicked to the oligomer via the same click
reaction. After cleavage of resin, the resulting crude PNA was purified by HPLC and
characterized by ESI-MS. By using “click-couple-click”, four PNA MBs, Py-1-Q,
Acridone-1-Q, Acridine-1-Q and Fluorescein-1-Q, were first synthesized (Table 3.1).
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Scheme 3.4 General synthesis of conventional PNA beacons via “click-couple-click”. a)
(E)-4-((4-ethynylphenyl)diazenyl)-N,N-dimethylaniline (7.5 equiv.), CuSO4⋅5H2O (15
equiv.), sodium ascorbate (60 equiv.), THPTA (30 equiv.), isopropanol/DMSO/H2O (1:1:2,
v/v/v), microwave 80 oC, 5 min; b) i) Fmoc azide monomer (5 equiv.), DIPEA (10 equiv.),
HBTU (5 equiv.), DMF, room temperature, 1.5 hours; ii) 20% piperidine/DMF; iii)
Ac2O/pyridine/DMF (1:25:25, v/v/v) c) i) same as a except that fluorophore-containing
alkynyl molecules were used instead of quencher; ii) TFA/TES (95:5, v/v).
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Table 3.1 Oligomers investigated in this study.
Name

Sequence (5'-3' or N-C)

Fmoc-1-Az

CTTTCCTTCACTGT-Az-K

Fmoc-2-Az

CATCTTTCCTTCACTGTTG-Az-K

Fmoc-1-Q

CTTTCCTTCACTGT-Q-K

Fmoc-2-Q

CATCTTTCCTTCACTGTTG-Q-K

pyrene-1-Q

pyrene-CTTTCCTTCACTGT-Q-K

acridone-1-Q

acridone-CTTTCCTTCACTGT-Q-K

acridine-1-Q

acridine-CTTTCCTTCACTGT-Q-K

Fluorescein-1-Q

Fluorescein-CTTTCCTTCACTGT-Q-K

pyrene-2-Q

pyrene-CATCTTTCCTTCACTGTTG-Q-K

Fluorescein-2-Q

Fluorescein-CATCTTTCCTTCACTGTTG-Q-K

CF-A*

ACAGTG A AGGAAAG

CF-MM-T*

ACAGTG T AGGAAAG

CF-MM-G*

ACAGTG G AGGAAAG

CF-MM-C*

ACAGTG C AGGAAAG

* CF = cystic fibrosis gene; CF-A is fully matched; MM-T, MM-G, MM-C are sequences
with mismatched T, G, C respectively.
The stability of the PNA:DNA duplexes was determined by thermal denaturation studies
after annealing of three PNA beacons to the perfectly matched or one-base mismatched
(MM) DNA target strands. The Tm values (Table 3.2) show that the matched duplex of all
PNA beacons demonstrated good discrimination over one base-MM targets (∆Tm=10-20
ºC), whereas the single-stranded PNAs did not display a melt transition. However, one
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base-MM duplexes all have melting temperatures above 42 ºC, indicating that no
discrimination between matched and one-base MM duplexes could be detected at room
temperature.
Table 3.2 Thermal stabilities of duplexes. Conditions:1 µM PNA and target in 100 mM
NaCl, 10 mM NaH2PO4, 0.1 mM EDTA, pH 7, 25oC.
Oligomers[a]

Tm (ºC)

∆Tm (ºC)

pyrene-1-Q

nd

--

pyrene-1-Q + matched DNA

60

--

pyrene-1-Q + MM-T

49

-11

pyrene-1-Q + MM-G

50

-10

pyrene-1-Q + MM-C

44

-16

acridone-1-Q

nd

--

acridone-1-Q + matched DNA

62

--

acridone-1-Q + MM-T

44

-18

acridone-1-Q + MM-G

50

-12

acridone-1-Q + MM-C

42

-20

acridine-1-Q

nd

--

acridine-1-Q + matched DNA

61

--

acridine-1-Q + MM-T

46

-15

acridine-1-Q + MM-G

49

-12

acridine-1-Q + MM-C

42

-19

Fluorescein-1-Q

--

--
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Fluorescein-1-Q + matched DNA

63

--

Fluorescein-1-Q + MM-T

46

-17

Fluorescein-1-Q + MM-G

51

-12

Fluorescein-1-Q + MM-C

48

-15

pyrene-2-Q

nd

--

pyrene-2-Q + matched DNA

62

--

pyrene-2-Q + MM-T

47

-15

pyrene-2-Q + MM-G

49

-13

pyrene-2-Q + MM-C

52

-10

Fluorescein-2-Q

48

--

Fluorescein-2-Q + matched DNA

63

--

Fluorescein-2-Q + MM-T

48

-15

Fluorescein-2-Q + MM-G

49

-14

Fluorescein-2-Q + MM-C

47

-16

[a]

Annealed samples;

To evaluate the ability of the PNAs to act as molecular beacons, their fluorescence emission
spectra were recorded in the absence or presence of DNA target strands at room
temperature. As shown in Figure 3.3a, the emission of matched duplex showed slightly
higher fluorescence intensity than that of single stranded pyrene-1-Q. Expectedly, the
discrimination of one-base MM duplexes from the matched duplex was not observed,
although MM-G and MM-C duplexed yielded same fluorescence intensity as that from the
SS PNA. However, emission of matched acridone-1-Q did not exhibit higher fluorescence
intensity than SS PNA, indicating no “turn-on” effect of acridone-1-Q as a MB.
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Interestingly, acridine-1-Q and its duplexes did not show fluorescence whereas high
fluorescence intensity was found after the samples were heated for hours, suggesting
decomposition of 9-aminoacridine.21 In the state of single strand, Fluorescein-1-Q still
showed comparable fluorescence to that from matched duplex, indicating low quenching
efficiency.

Fluorescence Intensity
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Figure 3.3 Fluorescence spectra of pyrene-1-Q. Conditions:1 µM PNA and target in 100
mM NaCl, 10 mM NaH2PO4, 0.1 mM EDTA, pH 7, 25oC. λex (pyrene-1-Q) = 345 nm.
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Figure 3.4 Fluorescence spectra of acridone-1-Q. Conditions:1 µM PNA and target in 100
mM NaCl, 10 mM NaH2PO4, 0.1 mM EDTA, pH 7, 25oC. λex (acridone-1-Q) = 390 nm.
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Figure 3.5 Fluorescence spectra of acridine-1-Q. Conditions:1 µM PNA and target in 100
mM NaCl, 10 mM NaH2PO4, 0.1 mM EDTA, pH 7, 25oC. λex (acridine-1-Q) = 395 nm.
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Figure 3.6 Fluorescence spectra of Fluorescein-1-Q. Conditions:1 µM PNA and target in
100 mM NaCl, 10 mM NaH2PO4, 0.1 mM EDTA, pH 7, 25oC. λex (Fluorescein-1-Q) =
493 nm.
To circumvent the weak “light-on” effect and poor discrimination of stemless PNA
beacons, a stem-loop PNA beacon which contains one fluorophore and one quencher was
designed and prepared. Considering that hairpin structure PNA was too stable to measure
in water18, a PNA sequence 2 with a one-base mismatched stem was synthesized via Fmoc
SPPS followed by “click-couple-click” of 2 to yield pyrene-2-Q and Fluorescein-2-Q by
using pyrene and fluorescein as the fluorophores (Table 3.1). The successful preparation
of pyrene-2-Q and Fluorescein-2-Q demonstrated that our “click-couple-click” method is
not sequence-sensitive, which would be of great benefit in developing various PNA MBs.
Thermal studies were performed to investigate the stability of these two stem-loop PNA
MBs. Surprisingly, the melting curves of pyrene-2-Q did not show binding, indicating no
stem was formed. Matched duplex of pyrene-2-Q has been found to have good
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discrimination over the one-base mismatched targets (10-15 oC) (Table 3.2). However, the
melting profiles of Fluorescein-2-Q displayed a Tm value of 48 oC and decent
discrimination between matched and one-base mismatched duplexes (14-16

oC),

demonstrating weak binding of the stem region of PNA oligomer 2.
In order to assess the ability as PNA MBs of Py-2-Q and Fluorescein-2-Q, fluorescence
studies were carried out. Disappointedly, their SS, matched duplex and MM’s all showed
similar fluorescence intensity, suggesting ineffective quenching.
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Figure 3.7 Fluorescence spectra of pyrene-2-Q. Conditions:1 µM PNA and target in 100
mM NaCl, 10 mM NaH2PO4,0.1 mM EDTA, pH 7, 25oC. λex (pyrene-2-Q) = 345 nm.
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Figure 3.8 Fluorescence spectra of Fluorescein-2-Q. Conditions:1 µM PNA and target in
100 mM NaCl, 10 mM NaH2PO4,0.1 mM EDTA, pH 7, 25oC. λex (Fluorescein-2-Q) =
493 nm.
3.3 Conclusion

Figure 3.9 Synthesis of conventional PNA beacons via “click-couple-click”.
In this chapter, an approach based on on-resin “click-couple-click” method has been
developed (Figure 3.9). It has several advantages: 1) fast; the microwave-assisted CuAAC
only takes 5 minutes and the coupling of second azide monomer 1.5 hours. the whole
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synthetic procedure of “click-couple-click” could be completed within 3 hours giving
quantitative yields without the need of preparing modified PNA monomers or extremely
different reaction conditions; 2) robust; the click reaction is mild and highly chemically
selective without any incompatibility issue with other functional moieties on reactants; the
reaction condition is operated easily because it is not sensitive to water, oxygen or light; 3)
facile; like other post-synthetic methodologies, multi-functionalization of PNA oligomers
could be achieved in one step; the resin-bound PNA-Q may be split into portions and each
portion would be used for the click of various fluorophores; in this way, a series of PNA
beacons could be synthesized and evaluated; this is also helpful in screening useful
fluorophores for the application of PNA MBs; 4) convenient; only washing the resin with
solvents is required for the work up that is operationally simple and fast; only final HPLC
purification after resin cleavage is needed.
In spite of convenience and versatility of “click-couple-click” method for the development
of PNA MBs have been demonstrated, the PNA MBs did not yield “turn-on” results or
discrimination of single-base mismatch at room temperature. The observed poor quenching
effect could be influenced by the sequence, as other studies have shown promising results
by using Fluorescein and DABCYL in stemless PNA MBs.4,5,8,18 Further studies are aimed
to improve the ability of PNA MBs such as attachment of two or more DABCYL molecules
on one end of the sequence or use of a different type of quencher to improve the quenching
effects.
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3.4 Experimental

Synthesis of Fmoc-1-Az and Fmoc-2-Az
PNA synthesis was performed on a 5 µmol scale using an automated ABI 433a peptide
synthesizer. SpheriTide-Lys(Boc)-Fmoc resin (loading 0.057 mmol/g) was used. The
synthesis was terminated without the final Fmoc deprotection. A small portion of the resin
was taken for characterization and the oligomer was cleaved/deprotected under standard
conditions for the characterization of Fmoc-1-Az and Fmoc-2-Az by Waters LCT Premier
ESI-MS. Other portions of the resin were taken and manipulated in manual peptide vessels.

General procedure for microwave on-resin click chemistry
The resin with PNA-Az was placed in isopropanol (0.25 mL) in a peptide vessel. Alkyne
(7.5 equiv.) in DMSO (0.25 mL), sodium ascorbate (60 equiv.) in water (0.2 mL), THPTA
(30 equiv.) in water (0.2 mL) and CuSO4·5H2O (15 equiv.) in water (0.1 mL) were added
to the resin successively. The resin was heated to 80 oC for 5 min by using CEM Discover
microwave reactor. After this, the solvent was drained and the resin was washed
sequentially with DMF, DCM, H2O, DMF and finally DCM.

General procedure for on-resin coupling reaction
The resin with PNA-Q was shaken in 2 mL 20% piperidine/DMF for 15 min to remove the
Fmoc protecting group and washed with DMF as well as DCM. Fmoc azide monomer (5
equiv.) was stirred in DMF (3 mL) in a round bottom flask on ice. HBTU (5 equiv.) and
DIPEA (10 equiv.) were added into the flask. The mixture was stirred on ice for 15 min
and added to the resin. The resin was then shaken at room temperature for 1.5 hr. After the
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reaction, the solvent was drained and the resin was washed with DMF as well as DCM.
The resin was then shaken in 2 mL 20% piperidine/DMF for 15 min to remove the terminal
Fmoc group and shaken in 3 mL Ac2O/pyridine/DMF (×2) for 15 min to cap the terminal
amine group. After “click-couple-click”, PNA was cleaved, purified and characterized
following by our previously reported procedure.22
Table 3.3 ESI-MS data of PNA sequences in this study.[a]
Name

Sequence (5'-3' or N-C)

Calc.
Found m/z m/z
[M+H]+

[M+H]+

Fmoc-1-Az

CTTTCCTTCACTGT-Az-K

4238.3296 4238.1883

Fmoc-2-Az

CATCTTTCCTTCACTGTTG-Az-K

5588.1495 5588.4866

Fmoc-1-Q

CTTTCCTTCACTGT-Q-K

4487.6560 4487.5036

Fmoc-2-Q

CATCTTTCCTTCACTGTTG-Q-K

5837.9668 5837.8019

Fmoc-Az-1-Q

Fmoc-Az-CTTTCCTTCACTGT-Q-K

4670.9842 4670.6735

Fmoc-Az-2-Q

Fmoc-Az-CATCTTTCCTTCACTGTTG-Q-K

6021.0658 6020.9719

Pyrene-1-Q

Pyrene-CTTTCCTTCACTGT-Q-K

4716.31

Acridone-1-Q

Acridone-CTTTCCTTCACTGT-Q-K

4725.1156 4725.753

Acridine-1-Q

Acridine-CTTTCCTTCACTGT-Q-K

4722.7174 4722.7524

Fluorescein-1-Q

Fluorescein-CTTTCCTTCACTGT-Q-K

4903.8030 4903.8539

Pyrene-2-Q

Pyrene-CATCTTTCCTTCACTGTTG-Q-K

6067.0258 6067.0434

Fluorescein-2-Q

Fluorescein-CATCTTTCCTTCACTGTTG-Q-K

6253.9048 6254.1522
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4716.745

a

Az = Azide monomer, Q = triazole linked DABCYL monomer, Pyrene = triazole-linked

pyrene monomer, Acridone = triazole-linked acridone monomer, Acridine = triazolelinked acridine monomer, Fluorescein = triazole-linked acridine monomer.

Calculation of the extinction coefficient for triazole linked DABCYL monomer,
triazole-linked acridone monomer and triazole-linked acridine monomer
The triazole monomers were prepared by Ms. Christie Ettles. A stock solution of
luminophore-triazole compounds was prepared in 10% DMSO/H2O (1 mg in 1.0 mL).
From this solution an intermediate diluted solution was prepared, which was used to
prepare the final solutions with a 10 µL, 20 µL, 30 µL, 40 µL, 50 µL, 60 µL, amd 70 µL
of the diluted solution in 1 mL H2O. Each solution was prepared in triplicate and the
absorbance of the solutions were evaluated within the range of 200-500 nm at a scan speed
of 600 nm/min.

Figure 3.10 Unpublished structures of triazole linked DABCYL monomer, triazole-linked
acridone monomer and triazole-linked acridine monomer (from left to right).
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Quantification of PNA oligomers
UV-visible spectrophotometer was used to determine the concentrations of PNA solutions.
10 µL of stock PNA sample was diluted to 1 mL for quantification and the absorbance at
260 nm of the sample was measured. 13700, 8800, 6600, 11700, 2490, 28400,23 42870,
43740 and 2100024 M-1cm-1 were used as ε260 values of A, T, G, C, pyrene-modified,
acridone-modified and acridine-modified monomer, respectively. The equation A=εcl was
used for calculation. ε260 of each PNA MB was the sum of the extinction coefficients of the
individual bases that comprises the oligomer.

Thermal denaturation experiments of oligomers
UV melting experiments were carried out to measure the Tm values of oligomers in this
study using the following ionic conditions: 100 mM NaCl, 10 mM Na2HPO4, 0.1 mM
EDTA, pH 7.0. Samples at 1 µM concentration were heated to 95 ºC, cooled to room
temperature over 1-2 hours, and placed at 4 ºC overnight. Denaturation was performed
from 15 to 90 ºC at a temperature ramp rate of 0.5 ºC/min. The Tm values are an average
of three measurements and are rounded to the nearest 1 ºC. The error in Tm values was ±
0.9 ºC. Tm values were estimated for cooperative transitions by the first derivative method.
Temperature dependent UV spectra that lacked upper and lower baselines, lacked
sigmoidal shape or were indistinguishable from SS PNA intramolecular melting were
deemed not be to cooperative transitions.
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Fluorescence studies of oligomers
Samples for all fluorescence studies were prepared in a quartz cell (path length: 1 cm) in
the same ionic conditions as for the denaturation experiments. Parameters for fluorescence
spectra are: excitation wavelength, 345 nm; scanning range, 350-600 nm; data interval, 0.1
nm; scan rate: 1 nm/s; temperature, 25 ºC.
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3.5 Supplementary information

Figure 3.11 ESI-MS spectra of Fmoc-1-Az calculated mass for C176H223N75O53:
1413.4014 [M+3H] 3+, 1060.3030 [M+4H] 4+.
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Figure 3.12 ESI-MS spectra of Fmoc-1-Q calculated mass for C192H238N78O53: 898.3070
[M+5H] 5+, 748.7572 [M+6H] 6+.
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Figure 3.13 ESI-MS spectra of Fmoc-Az-1-Q calculated mass for C198H247N83O55:
1168.4243 [M+4H] 4+, 934.9411 [M+5H] 5+.
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Figure 3.14 ESI-MS spectra of pyrene-1-Q calculated mass for C203H249N83O54: 944.1554
[M+5H]5+, 786.9641 [M+6H]6+.
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Figure 3.15 ESI-MS spectra of acridone-1-Q calculated mass for C201H252N84O55:
1182.1942 [M+4H] 4+, 945.9569 [M+5H] 5+.
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Figure 3.16 ESI-MS spectra of acridine-1-Q calculated mass for C201H251N85O54:
945.3568 [M+5H] 5+, 787.9653 [M+6H]6+.
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Figure 3.17 ESI-MS spectra of Fluorescein-1-Q calculated mass for C209H254N84O60:
981.5771 [M+5H] 5+, 818.1489 [M+6H]6+.
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Figure 3.18 ESI-MS spectra of Fmoc-2-Az calculated mass for C230H290N102O69: 932.2544
[M+6H] 6+, 799.2192 [M+7H] 7+.
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Figure 3.19 ESI-MS spectra of Fmoc-2-Q calculated mass for C246H305N105O69: 973.8069
[M+6H] 6+.
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Figure 3.20 ESI-MS spectra of Fmoc-Az-2-Q calculated mass for C252H314N110O71:
1004.3353 [M+6H] 6+, 861.0028 [M+7H] 7+.

103

Figure 3.21 ESI-MS spectra of pyrene-2-Q calculated mass for C257H316N110O70:
1214.2150 [M+5H] 5+, 1012.0138 [M+6H] 6+, 867.5844 [M+7H] 7+.
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Figure 3.22 ESI-MS spectra of Fluorescein-2-Q calculated mass for C263H321N111O76:
1043.1987 [M+6H] 6+, 894.3143 [M+7H] 7+.
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Figure 3.23 HPLC-UV absorption spectrum of pyrene-1-Q at 265 nm.

Figure 3.24 HPLC-UV absorption spectrum of acridone-1-Q at 265 nm.
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Figure 3.25 HPLC-UV absorption spectrum of acridine-1-Q at 265 nm.

Figure 3.26 HPLC-UV absorption spectrum of Fluorescein-1-Q at 265 nm.
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Figure 3.27 HPLC-UV absorption spectrum of pyrene-2-Q at 265 nm.

Figure 3.28 HPLC-UV absorption spectrum of Fluorescein-2-Q at 265 nm.
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13. CHAPTER IV: SYNTHESIS OF A (Gd(III)-DOTA)4-PNA
CONJUGATE AS A CONTRAST AGENT FOR MR IMAGING
A manuscript of this chapter is in preparation for submission. Xiaoxiao Wang, Mark Milne,
Francisco Martínez, Timothy J. Scholl and Robert H. E. Hudson*, Synthesis of a
Poly(Gd(III)-DOTA)-PNA Conjugate as a Potential MRI Contrast Agent via PostSynthetic Click Chemistry Functionalization.
4.1 Introduction
Molecular imaging has been employed in clinical medicine for the past decades by using
modalities such as magnetic resonance imaging (MRI), single photon emission
tomography (SPECT)/positron emission tomography (PET) and optical imaging. Although
SPECT/PET is very sensitive, the requirement of radioactive agents limits its application.
SPECT/PET is only used when suspect masses are evident or highly likely due to the
potential risks of radioisotope exposure. Optical imaging has been widely employed, but
disadvantages such as low efficiency of light transmission through tissues and difficult
quantification, cannot be neglected.1 Therefore, by comparison, MRI is an attractive
alternative for molecular imaging because it is non-invasive, does not require exposure to
radiation and provides three-dimensional images with high spatial resolution and high
contrast. After the introduction of MRI in the clinic in 1980s, it has shown unparalleled
power in diagnostic medicine, especially for the detection and characterization of diseased
soft tissues such as solid tumors.
The quality of MR images, including spatial resolution, signal-to-noise and contrast-tonoise ratios (SNR and CNR), has been substantially improved in the past years owing to
the use of higher magnetic fields and the development of safe and effective MRI contrast
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agents (CAs). MRI CAs are biocompatible magnetic materials that alter the longitudinal
(T1) and transverse (T2) relaxation rates of the surrounding water protons, therefore
enhancing image contrast in tissues of interest. They are generally categorized as T1 and T2
CAs based on their magnetic properties and relaxation mechanisms. CAs have become
essential for improving the image quality by increasing the image contrast between normal
and diseased tissues.2–5 Gadolinium [Gd(III)] chelates could increase T1 relaxation rate
(1/T1) and have been commonly used as T1 CAs by generating a positive image contrast.
Superparamagnetic iron oxide nanoparticles have been found more effective for increasing
T2 relaxation rate (1/T2), thus commonly used as T2 CA, which produces negative image
contrast. To date, the majority of MRI CAs used in clinical practice are Gd(III) chelates
(Figure 4.1), with over 10 million contrast enhanced MRI scans on an annual basis, because
of their high paramagnetism, favorable properties in term of relaxation enhancement,
relatively high stability, and tolerance in the body.
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Figure 4.1 Some of the Gd(III)-based MRI contrast agents currently used in the clinical
practice55 (copyright 2013 John Wiley and Sons).
Biocompatibility of the MRI CA is an important consideration for clinical applications.
Gd(III) ions are highly toxic in ionic form, acutely interfering with calcium channels and
protein-binding sites.6,7 Free Gd ions accumulate in the liver, spleen, kidney and bones and
have an LD50 = 0.2 mmol-1kg-1 in mice. To overcome this issue, Gd(III) ions are generally
complexed with chelating ligands to prevent tissue interaction and minimize toxic side
effects. Nevertheless, toxic Gd(III) ions may still be released from some of the chelates by
exchange with ions such as Zn2+, Ca2+, and Cu2+ in the body and by protonation of the
ligands at low pH that may cause chelate dissociation in vivo.8,9 A serious adverse reaction
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called nephrogenic systemic fibrosis may be associated to the use of Gd(III)-based CA in
a very small percentage of patients with renal malfunctions due to incomplete excretion
and possibly chelate disassociation of the agents.10 The US Food and Drug Administration
(FDA) has issued a black box warning to prohibit the use of Gd(III)-based CA in the
patients with renal malfunctions. Therefore, safer Gd(III) chelate-based MRI CAs are
required. The CAs need to be excreted after the contrast-enhanced MRI within hours.
Moreover, small Gd(III) chelates have a relatively low relaxivity and extravasate nonselectively from blood into the interstitium of both normal tissue and tumor, which has
been a major limitation for their clinical applications. Therefore, macromolecular Gd(III)
complexes have been proposed with higher relaxivity and prolonged retention in blood
circulation. It has been demonstrated that attaching Gd(III) chelates to macromolecules
slows down the rotational motion of the complexes, thus increaseing relaxivities.11
Macromolecular Gd(III) chelates have relatively higher relaxivity (r1) per Gd(III) ion than
that of small molecular Gd(III) chelates. For example, Gd-DTPA conjugated to polylysine
(PLL) with the molecular weights ranging from 3.3 up to 102 kDa has a r1 per Gd(III) ion
2.5 times higher than that of Gd-DTPA (measure at 2.4 T).12 P792 (Vistarem), a
macromolecular Gd-DOTA derivative (Figure 4.2), has a r1 relaxivity as high as 39 mM1second-1

per Gd(III) ion (0.47 T, 37 oC, in water) whereas r1 is 3.4 mM-1second-1 for Gd-

DOTA (0.47 T, 37 oC, in water).12,13 Higher relaxivity of macromolecular Gd(III)
complexes can help generate more efficient contrast enhancement. Thus they can be used
at significantly reduced doses. On the other hand, macromolecular CAs could effectively
target clinically important targets like DNA, mRNA or proteins/enzymes. For example,
targeted delivery of CAs into tumor tissues is crucial in cancer diagnostic MRI, because
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tumors are physiologically different from normal tissues and have leaky blood vasculature.
Tumor tissues usually abundantly express cancer-related biomarkers on cell surface,
extracellular matrix and angiogenic microvessels, which would be ideal targets for
molecular imaging. Therefore, ligands with high-binding affinity are essential for the
design of targeting CA in order to generate sufficient contrast enhancement of visualizing
these biomarkers with the aid of MRI.

Figure 4.2 Examples of macromolecule-based Gd(III) contrast agents55 (copyright 2013
John Wiley and Sons).
The 3’-ends of all fully processed eukaryotic mRNAs except most histone genes have a
polyadenylic acid [poly(rA)] tail. It consists of 200-250 adenine bases and occupies a
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significant role for mRNA stability, translation and transport.14–16 Poly(rA) tail has also
been recognized as a contributor in increasing length and as a platform to recruit mRNA
export factors.17 Polyadenylation of mRNA is a critical cellular event in the transcription
process for the maturation of all eukaryotic mRNAs. It is catalyzed by the enzyme poly(rA)
polymerase (PAP). Neo-PAP, a recently identified human poly(rA) polymerase, is
significantly over-expressed in human cancer cells in comparison to its expression in
normal or virally transformed cells, and may represent a tumor-specific target.18,19 This
suggests the poly(rA) tail acts as a potential malignancy specific target for the development
of hybridization probes.20 Probes that can recognize and bind to the poly(rA) tail of mRNA
might interfere with the full processing of mRNA by PAP and switch off protein synthesis.
Some small molecules like protoberberine alkaloids have been found to bind to poly(rA)
with high affinity leading to self-structure formation. Self-structure formation is very
significant with respect to its biological importance.20–22 On the other hand, it would be
interesting to apply antisense agents to binding poly(rA), blocking transcriptional
elongation and inhibiting the binding of transcriptional factors. Unlike regular antisense
DNA/RNAs, PNA with high affinity, specificity and stability, would have great potential
as a binder of poly(rA). It is also resistant to degradation in biological fluids as it is not
recognized by nucleases or proteases. It has been proven that a PNA probe could efficiently
recognize and bind to the poly(rA) tail.23 However, the studies using PNA as a
hybridization probe targeting poly(rA) via MRI has not been disclosed yet. Therefore, it
would be interesting to know if Gd(III)-chelated PNA would be a useful poly(rA)-targeted
CA.
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Macromolecular MRI CA are mainly prepared by conjugating Gd-DOTA and Gd-DTPA
to biocompatible macromolecules. Various bifunctional chelates of DTPA and DOTA have
been developed with attachments such as anhydride, N-hydroxysuccinimide activated
carboxylic acid, maleimide, alkynyl, and azide for conjugation. Bifunctional ligands and
small molecular Gd(III) chelates can be readily attached to high-molecular-weight
macromolecules including proteins,24 polymers,25 self-assembled peptide amphiphile
nanofibers26 and oligonucleotides27. The structures of some macromolecular Gd(III)-based
CAs are shown in Figure 4.2. Generally, there are two main strategies for labelling of PNA
with Gd(III) chelates. One of them is adding a Gd(III)-DOTA-containing monomer to the
sequence during solid-phase synthesis. For example, a Fmoc-Lys(DOTA)-OH has been
synthesized and inserted into PNA via solid-phase peptide synthesis.28 The imaging radiometal was chelated to the resulting PNA-DOTA. This type of labelling method has obvious
drawbacks, such as laborious and time-consuming synthesis of modified PNA monomers
and low yield of the coupling of the modified monomer due to potential incompatibility
with the chemical conditions (acidic or basic) of SPPS. Hence, the other strategy via postsynthetic labelling either in solution or on the solid-phase resin has been attempted. For
example, as Wickstrom reported, DOTA-(t-OBu)3COOH was coupled to the amino groups
of PNA oligomer on solid-phase followed by cleavage and Gd chelation.29 However, this
procedure is still tedious and includes deprotection, activation, coupling, capping,
deprotection again and Gd chelation. Also, protection of DOTA-COOH by t-OBu is
required in this study to avoid side reactions as carboxylic group would participate in the
coupling step. Therefore, an approach that is chemically selective, robust to functionalities
on PNA and operationally easy is still needed. With the inspiration by our previous work
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on post-synthetic click chemistry for functionalization of PNA,30 a labelling strategy
utilizing copper-catalysed click chemistry on polymer supported targets has been pursued.
Although most of PNA-CuAAC approaches were performed in solution, our attention
stayed on on-resin CuAAC, because it combines advantages of click chemistry and SPPS
in which an excess of reactants can be used and easily washed away from the solid support
without tedious workup; it is operationally easy to perform, and often to give quantitative
yields. On the other hand, post-synthetic functionalization of the PNA oligomer represents
a viable alternative to potentially reduce the overall synthetic effort, as well as introducing
a step that is amenable to structural diversification. To apply on-resin CuAAC to postsynthetically functionalize PNA, an Fmoc-azide PNA monomer in which a nucleobase was
replaced with an azide group has been synthesized.21 Up to four azide monomers have been
coupled into a PNA sequence by automated SPPS in different positions without any
concern for incompatibility.
Accumulation of Gd-containing probes at the target site is usually a main concern owing
to the limited concentration of the specific mRNAs in cancer cells. This has been addressed
in Wickstrom’s study in which multiple Gd chelators have been conjugated to PNA-peptide
dendrimer.29,31 In this way, the number of chelated Gd(III) ions per hybridization probe has
been increased. In this way, the number of chelated Gd(III) ions per hybridization probe
was increased by conjugation of PNA to a dendrimer labelled with Gd(III) chelators. They
demonstrated that the relaxivity per probe rose as the number of Gd(III) per probe rose.
To develop an effective PNA probe as a potential MRI contrast agent that can recognize
and bind to poly(rA), a hybridization probe, (Gd(III)-DOTA)4-PNA was designed and
synthesized in this work. Unlike a dendrimer-shape PNA-Gd probe, this probe is a comb118

shape PNA with four Gd chelators. It could bind to long Poly(rA) tail and form a triplex
structure, which could also concentrate Gd ions by taking advantage of the target sequence
(Figure 4.3), thus enhancing the contrast of MR images. The limitations such as tedious
work up and low yield of traditional approach that requires complicated protection strategy
for conjugation of PNA with Gd chelators, cannot be neglected. Therefore, a method based
on on-resin click chemistry is described in this chapter. A PNA sequence including four
azide monomers and ten thymine residues targeting poly(rA) tail was first synthesised.32–
34

Alkynyl-(Gd(III)-DOTA) molecules could be “clicked” to the PNA oligomer via on-

resin CuAAC to yield the hybridization probe, (Gd(III)-DOTA)4-PNA, which was
successfully characterized and evaluated.

Figure 4.3 Conceptual scheme of preparation and application of (Gd(III)-DOTA)4-PNA.
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4.2 Results and discussion
In order to optimize the derivatization chemistry, a test sequence, Fmoc-TTT-Az-K
(PNA1), containing one azide unit (Az, Scheme 4.1) was first synthesized. Without
purification, the crude resin-bound PNA1 was placed in a peptide vessel. Alkynyl-(Gd(III)DOTA)35–37 (30 equiv.), CuSO4·5H2O (60 equiv.), sodium ascorbate (240 equiv.), and the
ligand N,N’-dimethylethylenediamine (DMEDA) (60 equiv.) were added and
isopropanol/H2O(1:2, v/v) was used as the solvent. After the resin was shaken at room
temperature (12 h), Gd(III)-DOTA was found to be successfully attached to PNA1 with no
underivatized PNA1 being detected by LC/MS methods. The ESI-MS analysis showed
amass of 973.4175 [M+2H]2+ and 648.9204 [M+3H]3+ which were consistent with the
calculated mass of 973.5574 [M+2H]2+ and 649.3742 [M+3H]3+. We then proceeded to
prepare a PNA containing four azide monomers, PNA2 (Fmoc-K-Az-β-Az-β-Az-β-Az-KTTTTTTTTTT-K) by using regular PNA T monomers, Fmoc-Lys(Boc)-OH, Fmoc-β-AlaOH and Fmoc azide monomer (Scheme 4.1). A small portion of PNA was cleaved off the
resin and characterization was performed by reversed phase HPLC and ESI-HRMS. The
m/z of 1411.6052 [M+3H]3+ and 1058.9668 [M+4H]4+ agree well with the calculated m/z
of 1411.7679 [M+3H]3+ and 1059.0779 [M+4H]4+. Without purification, the resin-bound
PNA2 was subjected to CuAAC in the presence of excess alkynyl-(Gd(III)-DOTA)
(Scheme 4.1). By using this approach, Fmoc(Gd(III)-DOTA)4-PNA conjugate (Fmoc-KGd-β-Gd-β-Gd-β-Gd-K-TTTTTTTTTT-K) has been successfully synthesised with
quantitative conjugation yields via on-resin CuAAC. The excess reagents, solvents, and
catalyst were easily washed from the resin, whereas the workup to remove these materials
using solution phase methods can be laborious in our experience. ESI-HRMS of
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Fmoc(Gd(III)-DOTA)4-PNA conjugate showed 1324.0796 [M+5H]5+ and 1103.4063
[M+6H]6+ which are in accordance with the calculated mass of 1324.0326 [M+5H]5+ and
1103.5285 [M+6H]6+. After Fmoc deprotection and cleavage of the oligomer from the resin,
only the usual reversed phase HPLC purification was required. MS results of (Gd(III)DOTA)4-PNA

(K-Gd-β-Gd-β-Gd-β-Gd-K-TTTTTTTTTT-K)

showed

914.5258

[M+7H]7+ and 710.6509 [M+9H]9+ corresponding to the calculated mass of 914.2765
[M+7H]7+ and 711.3279 [M+9H]9+.

121

Scheme 4.1 Synthesis of (Gd(III)-DOTA)4-PNA by on-resin CuAAC. a) alkynyl(Gd(III)-DOTA) (30 equiv.), CuSO4·5H2O (60 equiv.), sodium ascorbate (240 equiv.),
DMEDA (120 equiv.), isopropanol/H2O(1:2, v/v), RT, overnight; b) TFA/TES (95:5, v/v).
To determine the stoichiometry of the binding of (Gd(III)-DOTA)4-PNA conjugate with
poly(rA), Job plots from UV-vis data were constructed and DNA-A10 was used as the
counterpart of (Gd(III)-DOTA)4-PNA. The results were obtained at two wavelengths (260
and 283 nm)24 (Figure 4.4). They indicated a binding stoichiometry of about 2 : 1 for
(Gd(III)-DOTA)4-PNA:DNA-dA10 complexes, which demonstrated the formation of
[(Gd(III)- DOTA)4-PNA]2 : DNA triplexes.33 Moreover, as the triplex formation of (PNA122

T8)2: poly(rA40) has been reported,32 we believe that (Gd(III)-DOTA)4-PNA would form a
triplex with poly(rA) with stoichiometry of 2:1.

Figure 4.4 Job plot of dA10 (4 µM/strand) and (Gd(III)-DOTA)4-PNA (4 µM/strand)
mixtures in the molar ratios of 0:100, 10:90, 20:80, 30:70, 40:60, 50:50, 60:40, 70:30,
80:20, 90:10. Solution conditions: 100 mM NaCl, 10 mM NaH2PO4, 0.1 mM EDTA, pH
7, 25 oC.
Thermal studies were performed by UV-melting in the presence of 2 µM [(Gd(III)DOTA)4-PNA]2 : poly(rA). Urea was used as chaotropic agent because the triplex was
found to be too stable to measure.38 The melting curves illustrates a biphasic profile with
Tm values of 56 oC and 85 oC in the presence of 6 M urea (Supplementary Information,
Figure 4.8), indicating the existence of triplex, which is also demonstrated by the Job plot
studies. Experiments were repeated thrice and the Tm values were measured from the first
derivative plots.
To evaluate our (Gd(III)-DOTA)4-PNA probe, we acquired its NMRD profiles at a series
of temperatures. A value of 5.6 mM-1s-1 is observed at 20 MHz and 25 oC per Gd ion (Figure
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4.6). NMRD profile of the triplex, [(Gd(III)-DOTA)4-PNA]2 : Poly(rA), has also been
achieved at 25 oC with r1 of 6.6 mM-1s-1 at 20 MHz. These findings are in good agreement
with other DO3A monoamide compounds (4-5 mM-1s-1) under similar conditions.39
Evaluation over the entire profile gives some indication of the solution structure of our
probe. An increase in relaxivity is seen at ~20 MHz for both (Gd(III)-DOTA)4-PNA and
the triplex, [(Gd(III)-DOTA)4-PNA]2 : Poly(rA) at 298K. This increase has been attributed
to the slowing of rotation,40 possibly due to the aggregation of the (Gd(III)-DOTA)4-PNA
and to a lesser extent the triplex formation in the presence of poly(rA). This is further seen
in the temperature studies where the increase in relaxivity at 20 MHz is not present for
higher temperatures, most likely due to the unfolding of the aggregate or destabilization of
the triplex formation (supplemental information). It is also noteworthy that triplex
formation of this probe with a poly(rA) tail would deliver 160–200 Gd3+ ions to a localized
microenvironment compared with dendrimeric developed contrast agents that have
achieved a loading of 150-200 chelators using a generation 6 PAMAM dendrimers.

41

While there are 256 potential sites available in a G6 PAMAM dendrimer, a typical loading
would be ~170 Gd3+ ions per dendrimer. Other dendrimers up to G10 have been
synthesised with a loading of 1860 Gd3+ ions.42 However, all these structures lack the
specificity that is necessary for molecular MRI and incorporation of molecules such as
polysaccharides,43–46 oligopeptides,47–50 proteins,47,51 antibodies52 and oligonucleotides53 is
needed. In comparison, our (Gd(III)-DOTA)4-PNA probe not only consists of targeting
oligomer, but also concentrate and deliver a high load of Gd ions.
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Figure 4.5 Longitudinal relaxivity (r1) of [(Gd(III)-DOTA)4-PNA]2:Poly(rA) triplex and
control linear (Gd(III)-DOTA)4-PNA with a constant 0.13 mM Gd(III) in 100 mM NaCl,
10 mM NaH2PO4, 0.1 mM EDTA, 6 M urea, pH 7, 25 oC.
4.3 Conclusions
In summary, a poly(Gd(III)-DOTA)-PNA probe has been prepared via on-resin click
chemistry, which is robust, operationally convenient and efficient for conjugation of PNA
with Gd chelators. The resulting PNA oligomer could recognize poly(rA) tail of mRNA
and form a stable triplex. The probe and its triplex with poly(rA) have been evaluated by
NMRD studies. An increase in relaxivity is seen at 20MHz for the triplex, [(Gd(III)DOTA)4-PNA]2 : Poly(rA) at 25 oC compared with (Gd(III)-DOTA)4-PNA. The
relaxivity of (Gd(III)-DOTA)4-PNA at 38 oC (~4.2 mM−1s−1) is comparable to the clinical
agents Magnevist® (gadopentetate dimeglumine, Gd-DTPA), Dotarem® (gadoterate, Gd125

DOTA), Prohance® (gadoteridol, Gd(HP-DO3A)) and Omniscan® (gadodiamide,
Gd(DTPA-BMA)) (3.5-3.8 mM−1s−1 at 20 MHz and 37 °C). By binding to poly(rA), Gd
ions would be significantly loaded to a localized microenvironment, which may improve
the enhancement of contrast in MR images.
4.4 Experimental
All chemicals and solvents were used as received unless specified. All solvents were
peptide synthesis grade, except water (18.2 MΩ⋅cm-1). The “Fmoc-azide monomer” was
prepared according to previously reported protocols.38 All reagents for synthesis of PNAs
were commercially available.

Synthesis of PNA1
PNA synthesis was performed on a 5 µmol scale using an automated ABI 433a peptide
synthesizer. PEGA-Lys(Boc)-Fmoc resin (loading 0.113 mmol/g) were used as the solid
support. The synthesis was terminated retaining the terminal Fmoc protecting group. A
small portion of the resin was taken for characterization and the oligomer was
cleaved/deprotected under standard conditions for the characterization of PNAs by ESIMS. Other portions of the resin were taken and manipulated in manual peptide vessels.

General procedure for on-resin click chemistry
Alkynyl-(Gd(III)-DOTA) (30 equiv.) in isopropanol (0.5 mL), CuSO4·5H2O (60 equiv.)
in H2O (0.33 mL), sodium ascorbate (120 equiv.) in H2O (0.33 mL), and N,N’dimethylethylenediamine (DMEDA) (60 equiv.) in H2O (0.33 mL) were added to the resin
in a peptide vessel. The resin was shaken at room temperature under N2 overnight. After
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the reaction was deemed completed by ESI-MS, the solvent was drained and the resin was
washed sequentially with DMF, DCM, H2O, MeOH and finally DCM. Then PNA was
cleaved from the resin, purified and characterized following by our previously reported
procedure.54
The crude poly(Gd(III)-DOTA)-PNA probe purified by reversed phase HPLC at 50 oC on
a 250 × 4.6 mm VARIAN C18 column eluted with a gradient of 0-5 min, 1% MeCN, 5-20
min, linear from 1% to 60% MeCN, 20-35 min, linear from 60% to 100% MeCN and 3540 min, linear from 100% MeCN to 100% H2O. Both H2O and MeCN solvents contain
0.05% TFA.

UPLC/Mass Spectroscopy of PNA oligomers
Ultra-performance liquid chromatography (UPLC) was performed using a BEH C18
column (particle size 1.7 µm; 1.0 i.d.×100 mm), Waters LCT Premier high-resolution
electrospray ionization mass spectroscopy (HR-ESI-MS) and diode array UV detectors.
The mobile phase was 100% H2O to 100% MeCN over 5 min by linear gradient, and 100%
MeCN over 2 min, at flow rate 0.1 mL/min. Both solvents contain 0.1% HCOOH.

Quantification of oligomers
UV-visible spectrophotometer was used to determine the concentrations of oligomer
solutions. The absorbance at 258 nm and 260 nm of the samples were measured for poly(rA)
and PNA, respectively. 9800 M-1cm-1 was used as ε258 of each nucleobase on poly(rA). The
equation below was used for calculating the concentration of nucleobases of poly(rA).
c (µM)=

1000×A258
9.8
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8800 M-1cm-1 were used as ε260 values of T. The equation below was used for calculating
the concentration of nucleobases of poly(Gd(III)-DOTA)-PNA.
c (µM)=

1000×A260
8.8

Thermal denaturation experiments of oligomers
UV melting experiments were carried out to measure the Tm values of oligomers in this
study using the following ionic conditions: 100 mM NaCl, 10 mM Na2HPO4, 0.1 mM
EDTA, pH 7.0. Samples at 2 µM concentration were heated to 95 ºC, cooled to room
temperature over 1-2 hours, and placed at 4 ºC overnight. Denaturation was performed
from 15 to 90 ºC at a temperature ramp rate of 0.5 ºC/min. The Tm values are an average
of three measurements and are rounded to the nearest 1 ºC. The error in Tm values was ±
0.5 ºC. Tm values were estimated for cooperative transitions by the first derivative method.
Temperature dependent UV spectra that lacked upper and lower baselines, lacked
sigmoidal shape or were indistinguishable from SS PNA intramolecular melting were
deemed not be to cooperative transitions.

General procedure for drawing Job plot by UV–vis method
A series solutions containing (Gd(III)-DOTA)4-PNA and dA10 in the ratios of 0:100,
10:90, 20:80, 30:70, 40:60, 50:50, 60:40, 70:30, 80:20, 90:10 and 100:0, respectively, were
prepared with the concentration of 4 µM at pH 7.0 in the condition of 100 mM NaCl, 10
mM Na2HPO4, 0.1 mM EDTA, pH 7.0. The absorbances at 260 nm and 283 nm were
plotted against the percentage of (Gd(III)-DOTA)4-PNA.
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Nuclear Magnetic Relaxation Dispersion (NMRD) studies of single strand, (Gd(III)DOTA)4-PNA and the triplex, [(Gd(III)-DOTA)4-PNA]2:Poly(rA)
The T1 NMRD profiles of 1 mL samples were acquired with a fast field-cycling NMR
relaxometer (SpinMaster FFC2000 1T C/DC, Stelar, s.r.l. Mede, Pavia (PV) - Italy). All
experiments were acquired with controlled temperatures (25, 38, 60 and 80 °C) and
changing the relaxation field in 30 steps, logarithmically distributed from 0.01 to 42.485
MHz (0.23 mT up to 1 T) and using an acquisition field of 16.2 MHz. The quantitative
relaxivity (r1) values were normalized to the reported gadolinium concentration for each
sample.
4.5 Supplementary Information
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Scheme 4.2 Synthesis of Gd(III)-DOTA-PNA1 by on-resin CuAAC. a) alkynyl-(Gd(III)DOTA) (7.5 equiv.), CuSO4·5H2O (15 equiv.), sodium ascorbate (30 equiv.), N,N’dimethylethylenediamine (DMEDA) (15 equiv.), isopropanol/H2O (1:2, v/v), r.t.; b)
TFA/TES (95:5, v/v).
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Figure 4.6 ESI-MS spectrum of PNA1 calculated mass for C79H104GdN25O24: 973.5574
[M+2H]2+.

Figure 4.7 ESI-MS spectrum of PNA2, calculated mass for C176H240N70O56: 1411.7679
[M+3H]3+, 1059.0779 [M+4H]4+.
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Figure 4.8 ESI-MS spectrum of Fmoc(Gd(III)-DOTA)4-PNA, calculated mass for
C252H352Gd4N90O84: 1324.0326 [M+5H]5+, 1103.5285 [M+6H]6+.
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Figure 4.9 HPLC-UV absorption spectrum of purified (Gd(III)-DOTA)4-PNA) (top)
and ESI-MS spectrum of (Gd(III)-DOTA)4-PNA) (bottom), calculated mass for
C237H342Gd4N90O82: 914.2765 [[M+7H]7+, 711.3279 [M+9H]9+.
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Figure 4.10 First derivative UV melting plots of [(Gd(III)-DOTA)4-PNA]2:poly(rA) at
260 nm at a concentration of 2 µM. conditions: 100 mM NaCl, 10 mM NaH2PO4, 0.1 mm
EDTA, 6 M urea, pH 7, 25 oC.
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Figure 4.11 NMRD profiles of (Gd(III)-DOTA)4-PNA at 25, 38, 60 and 80 oC. conditions:
100 mM NaCl, 10 mM NaH2PO4, 0.1 mm EDTA, 6 M urea, pH 7, 25 oC.
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15. CHAPTER V: BIOCONJUGATION OF OLIGOPEPTIDE TO
GOLD NANOPARTICLES FOR CT IMAGING VIA STRAINPROMOTED AZIDE-ALKYNE CYCLOADDITION (SPAAC)
Chapter 5 has been published as a research paper, and it is reprinted (adapted) with
permission from Xiaoxiao Wang, Pierangelo Gobbo, Mojmir Suchy, Mark S. Workentin*
and Robert H. E. Hudson*, RSC Advances, 2014, 4, 43087-43091. Copyright 2014 Royal
Society of Chemistry.
5.1 Introduction to gold nanoparticles and targeted CT imaging
Gold in its bulk scale is a popular material and has been widely used in jewelry, coinage,
and electronics. Gold has been found of great help in applications ranging from catalysts1–
3

to anti-arthritic medications.4 Unlike bulk- or molecular-scale gold, gold nanoparticles

(AuNPs) exhibit unique properties due to their size.5 The word nano describes any material
or property with dimensions on the nanometre scale (1-100 nm). In 2012, Dreaden and
coworkers have summarized AuNPs of various sizes and shapes with potential applications
in biomedicine.6 They could preferentially accumulate at tumor or inflammation sites and
enter cells through different but faster pathways than small molecules. Due to their facile
surface chemistry, AuNPs loaded with binding ligands can be used as artificial antibodies.
Their binding affinity can be precisely tuned by varying the density of binding ligands on
the surfaces. AuNPs can also efficiently convert light into heat, so they would lead to highly
specific thermal ablation of diseased or infected tissues. Multivalency of gold enables
AuNPs to shield unstable drugs or poorly soluble imaging contrast agents (CAs) and to
facilitate effective delivery to otherwise inaccessible regions of the body. Because of the
greater number of electrons of gold, AuNPs attenuate X-rays more effectively than iodine-

based CAs and therefore produces superior contrast for diagnostic computed tomography
(CT) scans. More importantly, it is possible that all of the above-mentioned advantages of
gold nanoparticles can be chemically combined into one construct allowing for
simultaneous targeting, diagnostic, and therapeutic functionalities which are helpful for a
particular patient or a disease.5
CT has become one of the most widespread molecular imaging technologies due to its high
sensitivity and spatial resolution, cost effectiveness, deep penetration capability, and facile
three-dimensional imaging reconstruction technique.7,8 To obtain high-quality CT imaging
of soft tissues, CAs are usually required such as iodine-based small molecules. However,
their disadvantages like short imaging time due to their fast clearance by kidney, renal
toxicity at a relatively high concentration,9 and especially non-specificity cannot be
neglected. Therefore, it is essential to develop novel targeted CT contrast agents to
overcome these shortcomings.
Nanoscale CAs for CT imaging have become extremely attractive thanks to the
development of nanotechnology. Various nanoparticles-based CAs, such as bismuth
sulfide nanoparticles,10–13 lanthanide-doped BaYbF5 upconversion nanoprobes,14
lutetium-based nanoparticulate CAs,15 ytterbium-based NPs,16,17 tantalum oxide NPs,18 and
AuNPs,19 have been employed for targeted CT imaging of different biological systems.
Among the diverse types of nanoscale CT CAs, AuNPs have been given considerable
attention owing to their better X-ray attenuation than iodinated CT contrast agents,
chemical stability, and good biocompatibility after surface functionalization.8,20–23
In 1971, Faulk and Taylor reported a technique to conjugate antibodies with colloidal gold
for direct electron microscopic visualization of Salmonella surface antigens.24 From then
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on, functionalized AuNPs have been extensively investigated in the fields of diagnostics,
bioimaging, drug and gene delivery, immunology and plasmonic biosensors.6,25–28 The
success of AuNPs in these fields has led to the Food and Drug Administration (FDA)
approval for AuNP-based in vitro diagnostic systems in clinical trials for cancer
treatments.29 To develop effective systems for targeted cancer diagnosis and therapies, it is
necessary to functionalize AuNPs with biomolecules such as DNA, proteins and peptides.
Peptide-AuNP conjugates have been exploited recently as CAs and nanocarriers in targeted
imaging for early stage cancer diagnosis and in the pharmaceutical field for targeted
intracellular drug/gene delivery, respectively.27,30
Thus our attention has been turned to the development of targeted CT CAs via
functionalization of AuNP with PNA or oligopeptides which would be a good start. The
main challenge of conjugation of peptides to AuNPs lies in understanding and controlling
the interfacial chemistry between the peptide and the nanomaterial surface on the molecular
scale. The reported strategies for bioconjugation of AuNPs with peptides include sulphurgold bond formation by the direct reaction of cysteine-terminated peptides with the gold
surface and electrostatic interactions between a particle and peptides that have been
coupled to bovine serum albumin (BSA).31 Although the first method is operationally easy
to perform, it is difficult to achieve a high degree of substitution. AuNP bioconjugation via
electrostatic interactions has good stability in aqueous solution, but the layer-by-layer
assembly results in large hydrodynamic radii of nanoparticles, which limits their
application under certain conditions, and offers poor control over the degree of
functionalization. Alternatively, a strategy via amide bonds formation involving a watersoluble carbodiimide, N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride
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(EDC), was developed for bioconjugation of AuNPs. Carboxylic groups can be activated
by EDC and reacted with primary amines through a condensation reaction to yield amide
bonds. Moreover, sulfo-NHS (N-hydroxy sulfosuccinimide) is used to increase the stability
of active intermediates in coupling reactions via the formation of active ester functional
groups with carboxylates. EDC/NHS coupling has been widely used in preparation of
AuNP-peptide conjugates.32 However, this method is still a challenge as quite often, the
peptides do not couple efficiently to AuNPs.33,34 Additionally, EDC/NHS coupling method
is not very selective as it involves the reaction between an amine and carboxylic acid
groups, which widely exist in peptides.35
In order to overcome the aforementioned difficulties, recent effort has focused on the use
of “click chemistry” for conjugation of AuNPs with biomolecules.33 For example, the
copper-catalyzed azide-alkyne cycloaddition (CuAAC) has been utilized to conjugate large
azido-containing AuNPs with alkyne functionalized horseradish peroxidase (HRP).34
However, the requirement of using copper ion as catalyst complicates the reaction and
could increase in vivo biological toxicity. The strain-promoted azide-alkyne cycloaddition
(SPAAC), also known as Cu-free alkyne-azide cycloaddition, can be used to overcome
these problems. The SPAAC reaction has been developed as a powerful bioconjugation
tool that displays outstanding chemoselectivity, excellent biocompatibility and takes place
under very mild reaction conditions. Since its first development,36 much effort has been
directed toward the synthesis of cycloalkynes with increased ring strain (to accelerate the
reaction) and higher hydrophilic character (for in vivo applications). The challenge behind
the syntheses of these interesting molecules relies on finding the right balance between
reactivity and chemoselectivity. Indeed, the greater the ring strain, the more susceptible the
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triple bond is to nucleophilic attack (i.e., addition reactions or rearrangement of
cyclooctynes) thus lowering the chemoselectivity towards the cycloaddition with an azide.
For example, it has been reported that highly strained biarylazacyclooctynone and
analogous bioconjugation reagents undergo rearrangement and addition reactions leading
to tetracyclic products.37 The rate of rearrangement was found to be accelerated as the
concentration of acid increased. This is problematic because concentrated TFA, such as 95%
TFA with scavengers, is the typical reagent for cleavage of peptides from solid supports
like Wang resin, Rink Amide resin, etc. together with the removal of the side chain
protecting groups. This limits the applications of strained alkynes for preparation of
clickable peptides. Additionally, strained alkynes have been shown to undergo side
reactions with cellular cysteines and other nucleophilic residues.38,39 However,
nucleophilic side chain functionalities, such as hydroxyl (Tyr, Ser, Thr), amino (Lys),
guanidine (Arg) or sulfhydryl (Cys), widely exist in bioactive peptides and may react with
highly reactive cyclooctynes through a nucleophilic attack.40 This also limits the
application of SPAAC. Interestingly, the application of interfacial SPAAC for
bioconjugation of AuNPs with peptides had not yet been disclosed prior to the work
described herein.
In this chapter, the development of a novel general method for the synthesis of AuNPpeptide bioconjugates is described that takes into account the side reactivity of the strained
alkynes and therefore combines an interfacial SPAAC with a post assembly deprotection
(PAD) for the conjugation of dibenzocyclooctyne (DBCO)-oligopeptides to small, watersoluble azide-AuNPs. It is shown that how this approach overcomes the aforementioned
drawbacks and extends the application of SPAAC to the bioconjugation of metallic
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nanoparticles in a quick, reliable and facile way. Importantly, the undesired side reactions
of the strained alkyne in the presence of concentrated TFA and with nucleophilic sites on
peptides are avoided through mild cleavage condition and retention of side-chain protecting
groups on the peptides during the SPAAC reaction. The protecting groups can then be
easily removed, i.e. post assembly deprotection (PAD), under reaction conditions that
preserve the integrity of the gold core, and the AuNP bioconjugate can be easily purified
by dialysis. Finally, the amount of conjugated peptide can be easily calculated.
5.2 Results and discussion
To showcase this SPAAC-PAD strategy an azide-AuNPs based on tri- and tetra-ethylene
glycol ligands that impart both water- and organic solvent-solubility to final AuNPs was
used. This is useful for manipulating the AuNP in organic solvents to facilitate both the
SPAAC reaction and the deprotection reaction, as well as maintaining solubility in water
for further in vivo applications.
The azide-AuNPs were prepared and characterized following our previously reported
procedure.41 Briefly, triethylene glycolmonomethyl ether AuNP (Me-EG3-AuNP) with a
gold core diameter of 3 ± 0.5 nm were synthesized via a modified Brust-Schiffrin method.
The azide ligand N3-EG4-SH was synthesized and introduced onto the surface of Me-EG3AuNP using a place-exchange reaction. In a typical synthesis 42.5 mmol of N3-EG4-SH
were stirred for 20 minutes in acetone and in presence of 50 mg of Me-EG3-AuNP.
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Figure 5.1 IR spectrum of azide AuNPs.
The free thiols were subsequently removed by trituration of the dried AuNP film first with
hexanes and followed by isopropanol. Azide-AuNPs were characterized by
thermogravimetric analysis (TGA), transmission electron microscopy (TEM) and FT-IR
spectroscopy. The IR spectrum of resulting AuNPs showed the appearance of asymmetrical
stretching of the azide group at 2110 cm-1 (Figure 5.1). TGA data indicated that the corona
of the AuNP is composed of 35% of azide ligands (Figure 5.2) and thus these nanoparticles
contain azide functionalities at a concentration of 0.745 µmol mg-1. Based on 1H NMR
spectrum and TGA data, and assuming that the nanoparticles have a spherical shape and
that their size is monodispersed, we can estimate a nanoparticle formula of Au1000(MeEG3-S)455(N3-EG4-S)245 (calculation reported in Experimental).
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Figure 5.2 TGA of control Me-EG3-AuNP (solid line) and of N3-EG4-AuNP (dashed line).
The effectiveness of our SPAAC-PAD approach is shown through the example of
bioconjugation of the arginylglycylaspartic acid (RGD) peptide. This peptide was chosen
because it has targeting relevance. It is well-known to be specifically recognized by the
integrin αvβ3 receptor and can act as tumour and angiogenesis marker.42,43
In Scheme 5.1 two potential routes are illustrated for bioconjugation of the azide-AuNP
with the RGD peptide. The first approach (Route 1, Scheme 5.1), involves preparing a
“naked” peptide consisting of a dibenzocyclooctyl (DBCO) moiety connected via a
polyethylglycol (PEG) linker to the RGD tripeptide (hereafter named “DBCO”-RGD).
After preparation PEG-containing RGD, DBCO was constructed to the peptide via
standard peptide coupling reaction. The resulting peptide, “DBCO”-RGD, was cleaved
from the resin and deprotected by using 95/5 TFA/TES. After purification, it was then
directly reacted with the azide-AuNP. The second approach (Route 2, Scheme 5.1) applies
a construct possessing a side-chain protected peptide fragment (DBCO-(PG)RGD). It is
noteworthy that dilute TFA (5/5/90 TFA/TES/DCM) was used as the reagent for cleavage
of the peptide from the resin and for retention of protecting groups on peptide side chains.
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The peptide reacted with the azide-AuNPs via an I-SPAAC and all protecting groups were
removed in a post-assembly deprotection step.

Scheme 5.1 Illustration of the attempted routes for the bioconjugation of azide-AuNPs with
RGD peptide via SPAAC-PAD. (a) Use of an unprotected peptide (route 1) or use of a
protected peptide (route 2), (b) and (c) molecular structures of “DBCO”-RGD and DBCO(PG)RGD. Protecting groups (PG) are Pbf and tBu.
To undertake the approach described by Route 1, RGD peptide was synthesized via
standard SPPS procedure using rink amide resin as the solid support (Scheme 5.2) and
DBCO acid was coupled to N-terminus of the peptide. Cleavage from the resin and
protecting group removal was done in one step by treatment with 95/5 TFA/TES. The
resulting native peptide was purified by HPLC and characterized by ESI-MS. The observed
molecular mass of 849.3472 was in agreement with the calculated mass (849.3657). In
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spite of this, close examination of the UV-spectrum of the peptide indicated that the
chromophore was changed from DBCO thus implying decomposition of DBCO had
occurred (supplementary information).

Scheme 5.2 Synthesis of DBCO-RGD peptide.
A control experiment was carried out to determine if the standard Fmoc-based
oligomerization chemistry cleavage condition of concentrated TFA induced decomposition
of DBCO. Starting with DBCO amine, we measured its purity by HPLC before and after
treatment with 95% TFA/DCM (rt, 1 hr). HPLC-UV absorption spectroscopy of the
reaction mixture, along with subsequent 1H NMR and high resolution mass spectral
analysis, clearly showed the complete consumption of starting material and the production
of several products (Figure 5.3 and Figure 5.4). The two major components of the mixture,
i.e. the peaks with retention time of 20-20.5 min and of 26-26.5 min do not correspond to
DBCO. On-line monitoring showed significant changes the UV spectrum indicating
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structural changes in the chromophore. The 1H NMR spectra of the two isolated
compounds confirmed neither was DBCO (supplementary information). Mass spectral
analysis showed that the earlier eluting peak retained the same mass as DBCO implying a
molecular rearrangement had occurred, 31 while the later eluting peak possessed a greater
mass. It's also noteworthy that the UV absorption spectrum of the first peak in Figure 5.4
showed strong absorbance at 344 nm, which has also been detected in UV spectrum of
“DBCO”-RGD, indicating that DBCO on peptide RGD had decomposed under the
standard cleavage condition of 95% TFA. To study the stability of the DBCO moiety
toward TFA, DBCO was exposed to a series of solutions of 0-50% TFA/DCM for 1 h at
room temperature. Under these conditions, DBCO was found to be stable when the TFA
concentration was less than 30%.

Figure 5.3 HPLC-UV absorption analysis at 265 nm of DBCO amine.
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Figure 5.4 HPLC-UV absorption analysis at 265 nm of decomposition of DBCO after
treatment with concentrated TFA.
Another control experiment was performed to model the interfacial SPAAC reaction by
using “DBCO”-RGD peptide with an azide, namely ω-azido-triethylene glycolmonomethyl ether (Me-EG3-N3) as the reactive partner. The reactions were carried out in
either water or acetonitrile solutions and the course of the reaction was monitored by
UPLC/ESI-MS. Only the two starting materials were detected over 4 hours, indicating that
the “DBCO”-RGD peptide and Me-EG3-N3 were not undergoing the SPAAC.
Independently it was determined that the Me-EG3-N3 was capable of participating in
SPAAC with DBCO. Therefore, “DBCO”-RGD lost the ability of click and cannot be used
as clickable peptide for bioconjugation of AuNPs. As a control for further study, the
peptide “DBCO”-RGD was still added into azide-AuNPs (azide group:peptide, 1 : 1.2
ratio). The mixture was stirred in water at room temperature for 1 h. After removal of
solvent, AuNPs were purified by centrifugal filtration (Millipore centrifugal filter units
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MWCO 10 kDa). As expected, characterization of these AuNPs by IR spectroscopy
showed the absorption of the azide group at 2110 cm-1 was still present with similar
intensity to the starting material, which indicated lack of SPAAC reactivity, and showed
no stretching at 1685 cm-1 corresponding to the amide functional groups.
To circumvent the problem of decomposition of DBCO, Route 2 was devised. First we
prepared DBCO-(PG)RGD by using a mild cleavage condition and it was then clicked to
the azide-AuNP and subsequently the peptide was deprotected (Scheme 5.1). To synthesize
the DBCO-(PG)RGD, the acid sensitive 2-chlorotritylchloride resin was used as solid
support. The synthesis of DBCO-containing peptide followed the above procedure, except
that the cleavage was performed with TFA/TES/DCM (5/5/90). This treatment effected the
cleavage of the peptide from the resin but left the protecting groups intact and did not
destroy DBCO (Scheme 5.3). The resulting protected peptide was purified by HPLC and
characterized by ESI-MS. The UV spectrum of DBCO-(PG)RGD showed the agreement
with DBCO with absorbance at 290 nm and 308 nm. A model click was carried out with
DBCO-(PG)RGD and Me-EG3-N3 in acetonitrile. Characterization of the reaction by
UPLC/ESI-MS showed successful click, indicating that DBCO was not destroyed in the
cleavage step. Then SPAAC between azide-AuNPs and DBCO-(PG)RGD was simply
performed by adding them (azide:peptide, 1 : 1.2) in acetonitrile and stirring the resultant
mixture at room temperature for 1 h (Figure 5.5). After reaction, the AuNPs were purified
by using centrifugal filtration (Millipore centrifugal filter units MWCO 10 kDa) and
washed with 60% MeOH/H2O until no unreacted peptide was observed in the UPLC/ESIMS analysis of the filtrate. The unreacted peptide was recovered from the filtrate and
washings and the amount indicates that approximately 31% of the azide groups on AuNPs
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had reacted. Therefore, the approximate nanoparticle formula can be calculated as
Au1000((PG)RGD-linker-S)75(N3-EG4-S)170(MeEG3S)450. The IR spectrum of the purified
(PG) RGD-AuNPs showed that the azide stretching mode at 2110 cm-1 had markedly
decreased while it had not changed in Route 1 (Figure 5.6). Additionally, concomitant with
the azide disappearance the appearance of stretching at 1685 cm-1 corresponding to the
amide functional groups was observed, indicating that the protected peptide was covalently
bonded to the AuNP via SPAAC.

Scheme 5.3 Synthesis of DBCO-(PG)RGD peptide.
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Figure 5.5 IR spectrum of PG-RGD-AuNPs.

Figure 5.6 IR spectrum of RGD-AuNPs.
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Figure 5.7 Bioconjugation of AuNPs with RGD peptide via SPAAC-PAD, 1) acetonitrile,
room temperature, 1 h; 2) 90% TFA/DCM, room temperature, overnight; and AuNP size
distributions obtained from the corresponding TEM image of RGD-functionalized AuNPs
via SPAAC-PAD.
To remove the protecting groups of the peptide, the AuNPs were then treated with 90%
TFA/DCM at room temperature overnight to ensure complete deprotection. It is important
to note that these small oligo-ethylene glycol-based AuNP are perfectly stable under these
acidic conditions. TEM images recorded before and after this acidic treatment confirmed
that the relatively harsh condition for PAD did not adversely affect the AuNP size
distribution (Figure 5.7). The obtained RGD-AuNPs were then purified by dialysis using
cellulose ester dialysis membranes (6-8 KDa MWCO).
To further confirm that the interfacial SPAAC reaction had proceeded, the deprotected
RGD-AuNPs were reacted with molecular iodine. Oxidation of AuNPs with iodine
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dissolved the gold into a mixture of Au(I) and Au(III) complexes and released the corona
ligands as disulphides.44 The structure of the most possible disulphide molecule produced
by this reaction is shown in Figure 5.8. The mixture of disulphides was characterized by
ESI-MS and the mass 1365.6084 [M+H]+ m/z agrees well with the calculated mass of
1364.5992 for the proposed disulphide 1. Importantly the mass for the corresponding
disulphide with the protected peptide was not observed, indicating that the complete
deprotection was achieved. This confirms the successful bioconjugation of AuNPs with a
short oligopeptide via SPAAC-PAD without interference with side chains of the peptide.
Moreover, efficient substitution was achieved on the surface of small size AuNPs with 31%
of the azide groups reacting with the RGD peptide. This result is comparable with the
reported conjugation of AuNPs with peptides via covalent bonding,20 with the difference
that this AuNP-bioconjugate was obtained through a simple and rapid pour-and-mix
chemistry under ambient temperature and atmosphere while the purification only involved
centrifugation and dialysis. The final calculated molecular raw formula of this AuNP is
Au1000(RGD- linker-S)75(N3-EG4-S)170(MeEG3S)450.
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Figure 5.8 Oxidative degradation of RGD-AuNPs by iodine. Disulfide 1 was characterized
by ESI-MS. Calculated 1364.5992 and found 1365.6084 [1+] m/z.
To test the versatility of this method we employed a peptide with different nucleophilic
residues. In particular, because it has been reported that in presence of reduced
peptidylcysteine residues, strained cyclooctynes mainly react via thiol-yne addition instead
of SPAAC reaction, 33 we decided to synthesize a CRGDK peptide and conjugate it to the
azide-AuNPs via our SPAAC-PAD strategy (Scheme 5.4). This peptide has an additional
interest because it is a neuropilin-1 (Nrp-1) receptor-targeted peptide for cancer
treatment.32,45,46
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Scheme 5.4 Synthesis of DBCO-(PG)CRGDK peptide.
For these experiments, we followed the same procedure as previously discussed with the
noted exception. The CRGDK peptide was synthesized via standard Fmoc SPPS method
and DBCO acid was coupled to the N-terminus. A change in the acid strength for resin
cleavage (0.5% TFA/DCM) was made to preserve the trityl thioether protecting group of
cysteine. After SPAAC-PAD, the CRGDK-functionalized AuNPs were characterized by
IR (Figure 5.9). The azide stretch in the IR spectrum became weaker compared to the azideAuNPs before conjugation and the stretching at 1685 cm-1 corresponded to the functional
groups of peptide bond appeared, suggesting successful conjugation through the I-SPAACPAD. Also, a new absorbance at 2692 cm-1 indicated the existence of the thiol group of
cysteine and shows that the side chain of cysteine that would otherwise react with
cyclootyne via thiol-yne addition did not interfere with the I-SPAAC reaction with the aid
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of PAD. Decomposition of the AuNPs by treatment with excess I2 followed by ESI-MS
analysis showed the two most possible disulfide molecules expected after a successful ISPAAC-PAD, and no trace of protected peptide was found (Scheme 5.5). Therefore, our
strategy showed to be also effective in creating small AuNP-oligopeptide bioconjugates in
presence of nucleophilic residues that could otherwise attack the strained alkyne bond.

Figure 5.9 IR spectrum of CRGDK-AuNPs.
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Scheme 5.5 Oxidative decomposition of CRGDK-AuNPs by iodine. Disulfides 2A and 2B
was characterized by ESI-MS. 2A calculated 1600.6645 and found 800.2318 [M+2H]2+.
2B calculated 1242.5162 and found 621.6824 [M+2H]2+.
Preliminary in vivo CT imaging of mice with brain and leg tumor, respective, have been
performed by using RGD-functinalized AuNPs as the CA. The results showed that AuNPs
were diffused within 3 minutes throughout the body without detectable contrast at the site
of tumor, although contrast was detected in the bladder. This issue may be addressed by
enlarging the size of AuNPs for the further improvements of CT images.
5.3 Conclusion
In summary, we have created a new, efficient, easy method to implement general approach
to the synthesis of AuNP-peptide bioconjugates that combines the I-SPAAC reaction with
post assembly deprotection. Using this strategy, peptides with protected side chains can be
conjugated onto gold nanoparticles via I-SPAAC and all protecting groups can then be
easily removed by PAD. The mild reaction conditions preserve the integrity of the alkyne
so that it may perform the SPAAC reaction and the conjugated AuNPs are sufficiently
robust to undergo peptide deprotection without deleterious effects. The approach presented
herein usefully expands the repertoire of existing methods and presents an easy, reliable
and quick way to functionalize AuNPs with short oligopeptides where the extent of
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incorporation of the interfacial biomolecule can be easily quantified. We anticipate that the
demonstrated methodology for peptide-AuNP bioconjugation via the SPAAC-PAD will
enable the fabrication of gold nanoparticles with a high degree of complexity with
biomolecules for a variety of applications in targeted cancer diagnosis and therapies.
Further modification and functionalization of AuNPs for better results of targeted CT
imaging is currently underway.
5.4 Experimental
Synthesis of “DBCO”-RGD peptide
The “DBCO”-RGD peptide was synthesized manually via standard Fmoc SPPS procedure
by using rink amide MBHA resin as solid support. Briefly, the peptide chain including
RGD and a linker was grown on the resin and DBCO acid was coupled to terminate the
peptide. The coupling of each residue used 5 equiv. (relative to the loading of resin) Fmocprotected amino acids, 5 equiv. of HBTU and 10 equiv. of DIPEA in a DMF solution for
4 hours. During the synthesis, Fmoc protecting group was deprotected using 20%
piperidine/DMF (v/v) for 15 minutes. At the end of the synthesis, DBCO acid was
conjugated to the peptide following the above-mentioned procedure except that 1.1 equiv.
DBCO acid, 1.1 equiv. HBTU and 2.2 equiv. DIPEA were used. After the completion of
the synthesis, the resin was washed with DMF and DCM (each for four times) and dried
under vacuum for 24 hours. Cleavage of the expected peptide and the removal of side chain
protecting groups from the dried resin were performed by suspending the resin in cleavage
cocktail containing TFA (95%) and TES (5%) for 1 hour. The filtration was concentrated
to a viscous solution by flushing N2. After the precipitation in ice cold ether, the crude
product was collected, dissolved in MQ water and freeze-dried. The characterization of
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“DBCO”-RGD peptide with calculated mass 849.3657 [M+H]+ was performed by Waters
LCT Premier ESI-MS and found 849.3395 [M+H]+. Purity: 98.7% determined by HPLC
with a C18 column and using a linear gradient of acetonitrile and MQ water containing
0.05% TFA.
Synthesis of DBCO-(PG)RGD peptide
The DBCO-(PG)RGD peptide was synthesized manually via standard Fmoc SPPS
procedure by using 2-chlorotrityl chloride resin as solid support. The coupling of the first
residue used 1.5 equiv. Fmoc-protected amino acid and 4 equiv. of DIPEA in a DCM
solution for 2 hours. Other amino acid couplings and DBCO acid coupling were carried
out followed by the above-mentioned procedure. Cleavage of the protected peptide from
the dried resin was performed by suspending the resin in cleavage cocktail containing TFA
(5%), TES (5%) and DCM (90%) for 1 hour. The filtration was concentrated to a viscous
solution by flushing N2. The crude product was dissolved in acetonitrile and purified by
HPLC. The characterization of DBCO-(PG)RGD peptide with calculated mass 1259.5784
[M+H]+ was performed by ESI-MS and found 1260.5776 [M+H]+. Purity: 96.5%
determined by HPLC with a C18 column and using a linear gradient of acetonitrile and
MQ water containing 0.05% TFA.
Synthesis of DBCO-(PG)CRGDK
The synthesis was performed as described for DBCO-(PG)RGD. Cleavage of the protected
peptide was performed by suspending the resin in cocktail containing 0.5% TFA/DCM for
15 min. The filtration was concentrated to a viscous solution by flushing N2. The crude
product was dissolved in acetonitrile and purified by HPLC. The characterization of
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DBCO-(PG)CRGDK with calculated mass 1659.7393 [M+H]+ was performed by ESI-MS
and found 1660.6294 [M+H]+. Purity: 94.8% determined by HPLC with a C18 column and
using a linear gradient of acetonitrile and MQ water containing 0.05% TFA.
Synthesis of azide AuNPs
In a typical synthesis, 50.0 mg of Me-EG3-AuNP were transferred into a clean 25 mL round
bottom flask. This compound was dissolved in 10 mL of acetone. Then 10.0 mg (42.5 µmol)
of N3-EG4-AuNP were transferred into this solution. The reaction was stirred vigorously
for 20 min. After this time, the acetone was immediately evaporated off. The thin film of
nanoparticles was washed first with hexanes (in which AuNP are not soluble) and the
solvent was removed under vacuum. Subsequently the film was quickly rinsed with
isopropanol three times. This entire washing procedure was repeated three times until the
odour of the thiol was gone. 44.9 mg of nanoparticles were obtained. The nanoparticles
were dissolved readily in H2O, acetone, acetonitrile, methanol, ethanol, DMF, DMSO and
DCM with little to no aggregation and characterized by 1H NMR and IR. 1H NMR (CD3CN,
400 MHz): δH (ppm): 3.60, 3.49, 3.39, 3.31. 1H NMR (D2O, 400 MHz): δH (ppm):3.66,
3.57, 3.43, 3.32. IR (KBr disk, cm-1): 2921, 2871, 2101, 1443, 1349, 1292, 1244, 1198,
1119, 1033.
Bioconjugation of azide AuNPs with RGD peptide via SPAAC-PAD
DBCO-(PG)RGD (1.2 equiv. of DBCO relative to azide substitution on AuNPs) and azide
AuNPs were mixed in 3 mL acetonitrile at room temperature for 1 hour. After that, the
AuNPs were purified by using centrifugal filter devices (10KDa MWCO) and washed with
60% MeOH/H2O until no unreacted peptide can be found be ESI-MS. The resulting AuNPs
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were treated with 90% TFA/DCM at room temperature overnight and the solvent removed
by flushing N2. The obtained AuNP-RGD were purified by dialysis against water using
Cellulose ester dialysis membranes MWCO of 10 kDa for 2 days and characterized by IR,
TEM and ESI-MS. IR (KBr disk, cm-1): 3370, 2930, 2110, 1685, 1109.
Bioconjugation of azide AuNPs with DBCO-(PG)CRGDK
The bioconjugation was performed as described for AuNP-RGD. The obtained AuNPCRGDK after SPAAC-PAD was characterized by IR and ESI-MS. IR (KBr disk, cm-1):
3370, 2930, 2692, 2110, 1685, 1446, 1346, 1109.
Calculation of nanoparticle formula
Assuming that the AuNPs are spherical and that their size is monodisperse (3 nm) it is
possible to calculate an approximate molecular formula for azide AuNPs. The number of
gold atoms (NAu) can be calculated using the following formula:

=

6

Where ρ is the density of the face centered cubic (fcc) gold lattice (19.3 g⋅cm-3), d is the
average diameter of the nanoparticles in centimeters found from the TEM images, MAu is
the mole atomic weight of gold (196.9665 g mol-1), and NA is Avogadro constant.
The number of thiol ligands surrounding the gold core (NL) can be calculated using the
following formula:

=
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%
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Where W% is the percentage of mass loss due to the organic ligands found through TGA
measurements, MWMe-EG3-S is the molecular weight of the thiolate ligand, MWN3-EG4-S is
the molecular weight of the azide thiolates ligand, and M% is the mole percentage of azide
ligand.
5.5 Supplementary Information

Figure 5.10 ESI-MS analysis of “DBCO”-RGD. Calculated mass 849.3657 [M+H]+ and
found mass 849.3472 [M+H]+.
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Figure 5.11 ESI-MS analysis of DBCO-(PG)RGD. Calculated mass 1259.5784 [M+H]+
and found mass 1260.5776 [M+H]+.

Figure 5.12 ESI-MS analysis of DBCO-(PG)CRGDK. Calculated mass 1659.7393
[M+H]+ and found mass 1660.6294 [M+H]+.

26

Figure 5.13 ESI-MS analysis of disulfide 1 from re-oxidation of AuNP-RGD by iodine.
Calculated mass is 1364.5992 and found mass is 1365.6084 [M+H]+ for Disulfide 1.
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Figure 5.14 ESI-MS analysis of disulfide 2A (top) and 2B (bottom) from re-oxidation of
AuNP-CRGDK by iodine. Calculated mass is 1600.6645 and found mass 800.2318
[M+2H]2+ for 2A. Calculated mass is 1242.5162 and found mass 621.6824 [M+2H]2+ for
2B.

28

Figure 5.15 HPLC-UV absorption analysis at 265 nm of “DBCO”-RGD.

Figure 5.16 HPLC-UV absorption analysis at 265 nm of DBCO-(PG)RGD.
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Figure 5.17 HPLC-UV absorption analysis at 265 nm of DBCO-(PG)CRGDK.

Figure 5.18 1H NMR spectrum of azide AuNP recorded in acetonitrile-d3 and calibrated
against residual acetonitrile (*).

30

Figure 5.19 TGA of control Me-EG3-AuNP (solid line) and of N3-EG4-AuNP (dashed line).

Figure 5.20 TEM image of azide AuNPs.

31

Figure 5.21 TEM image of RGD-AuNPs.

32

Figure 5.22 1H NMR (top) and ESI-MS (bottom) spectra of DBCO amine (found mass:
278.1120 [1+]). 1H NMR Spectra were recorded in CDCl3.

33

Figure 5.23 1H NMR (top) and ESI-MS (bottom) spectra of isolated compound (found
mass: 278.3239 [1+]). 1H NMR Spectra were recorded in D2O/ACN-d3 (2:1).

34

Figure 5.24 1H NMR (top) and ESI-MS (bottom) spectra of isolated compound (found
mass: 302.0555 [1+]) after treatment of DBCO amine with concentrated TFA. 1H NMR
Spectra were recorded in CDCl3.
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Figure 5.25 IR spectrum of DBCO-PG-RGD.
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16. CHAPTER VI: ONCLUSION AND OUTLOOK
With superior hybridization features, resistance to nucleases and proteases, chemical
robustness and excellent sequence discrimination, PNA has become one of the most
attractive artificial nucleic acids. PNA has demonstrated its utility as hybridization probes
for molecular diagnostics, potential for antisense/antigene therapy as well as targeted
imaging. However, the difficulties in preparing modified PNA probes remain in PNA
chemistry, because it is usually expensive, time-consuming and labor-intensive to
functionalize PNA. In order to prepare desired PNAs more efficiently and cost-effective,
methodologies for the functionalization of PNA via post-synthetic click chemistry has been
explored and discussed in this thesis. The developed approaches are convenient, simple
and versatile, and provided a route to diverse PNA probes that have been evaluated.
Chapter II introduced the synthesis of quencher-free PNA molecular beacons by a
simultaneous attachment of fluorophores via on-resin CuAAC for the first time. This easy,
flexible method showed variability in development of single- or multiple-labeled PNAs.
The pyrene-based stem-loop PNA beacon has shown its promise in the detection of cystic
fibrosis genes and obviously could be extended to many target sequences or fluorophores.
Chapter III presented the development of conventional PNA molecular beacons via a
"click-couple-click" strategy. A quencher and a fluorophore can be attached to a PNA
oligomer sequentially without the need of complicated protection and deprotection of
reactive sites of PNA. Microwave-assisted on-resin CuAAC has been applied for the first
time to PNA, to the best of my knowledge, and the procedure of "click-couple-click"
approach is fast, robust, efficient and operationally simple. Given that PNA probes are still
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difficult and very expensive to be obtained, the presented method in this chapter will be of
great help in rapidly and easily synthesizing various PNAs. A series of PNA beacons have
been successfully synthesized and characterized. This methodology complements the one
presented in Chapter II for the synthesis of homo-dimer MBs. Thus, this method gives
more synthetic variability in the choice of fluorophore-quencher or donor-acceptor pairs
for customized MB construction.
Expanding on the aforementioned click chemistry, Chapter IV showed the preparation of
a Gd(III)-containing PNA hybridization probe as a potential MRI contrast agent. Four units
of alkynyl Gd(III)-DOTA were clicked to a PNA simultaneously and the resulting oligomer
has been demonstrated useful in binding with the poly(rA) tail. This method significantly
simplify the procedure for the conjugation of a PNA probe with Gd chelators which
generally requires coupling of chelators like DOTA, protection and/or deprotection of
nucleobases as well as Gd chelation. By bindng to poly(rA) to form a triplex, the probe,
(Gd(III)-DOTA)4-PNA, would concentrate and deliver a high load of Gd ions in a
microenvironment.
As AuNPs are promising CT contrast agents, bioconjugation of PNAs to AuNPs for
targeted CT imaging would also be of great interest. The use of a peptide would be a good
start for investigation of the conjugation methods. In chapter V, peptide-decorated AuNPs
via strain-promoted azide-alkyne cycloaddition and post assembly deprotection (SPAACPAD) is presented. SPAAC was applied for the bioconjugation of AuNPs because of the
benefits of copper-free click chemistry. Due to the possible decomposition of cyclooctyne
under regular conditions for peptide cleavage, post assembly deprotection has been
proposed and proven to be helpful for the conjugation. This method has been demonstrated
42

useful and convenient for functionalization of small, water-soluble gold nanoparticles with
oligopeptides. Future studies on decoration of AuNPs with PNAs by using SPAAC-PAD
should be performed.
To expand the application of PNA and thoroughly investigate the properties of PNA probes,
synthetic protocols which are more cost-effective, robust, convenient and versatile for are
needed. Therefore, with the chemistry and procedure developed during this thesis, rapid
preparation of various PNA probes is made possible, which may reduce the difficulties in
functionalization of PNAs as performed in research laboratories and commercial
companies.
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